NIH_SPENDING_CATS: Aging;Biotechnology;Diabetes;Eye Disease and Disorders of Vision;Macular Degeneration;Neurodegenerative;Neurosciences

ORG_CITY: SPRINGFIELD

ORG_NAME: REVOPSIS THERAPEUTICS, INC.

ORG_STATE: IL

PHR: PROJECT NARRATIVE RevOpsis Therapeutics is developing RO-104, a trispecific surrobody that targets Vascular Endothelial Growth Factor-A (VEGF-A), Vascular Endothelial Growth Factor-C (VEGF-C) and Angiopoietin-2 (Ang-2) for the treatment of retinal diseases, which has been extensively tested in vitro and in vivo in smaller mammals (rats and rabbits). RO-104 shows comparable half-life and higher affinity for VEGF-A and Ang-2, with synergistic binding to Ang-2 when binding simultaneously, than the current standards of care and first in class binding to VEGF-C with the ability to bind all three targets simultaneously. In this SBIR Phase II, RevOpsis Therapeutics will further develop RO-104 as a new therapeutic for retinal diseases through relevant IND- enabling preclinical models.

PI_NAMEs: XU, LI  (contact)

PROGRAM_OFFICER_NAME: LEE, PAEK-GYU

PROJECT_TERMS: Accounting;Address;Adherence;Affect;Affinity;Age related macular degeneration;aging population;American;Angiopoietin-2;Animal Model;Animals;Antibodies;Area;Awareness;Back;bevacizumab;Binding;Biological;Biological Process;Blindness;Blood;Blood Chemical Analysis;Blood Vessels;Caring;Chemistry;Child;Cicatrix;Clinical;Clinical Trials;diabetic;Diabetic Retinopathy;Disease;Dose;drug discovery;Drug Kinetics;Dryness;Edema;effective therapy;efficacy study;Engineering;experience;Eye;Facilities and Administrative Costs;follow-up;Formulation;Frequencies;Fright;Future;Goals;Growth;Half-Life;Health;Hemorrhage;Histoplasmosis;Human;human old age (65+);improved;in vitro testing;in vivo;Individual;Injections;interest;intravitreal injection;Investigational Drugs;Investigational New Drug Application;Lead;Legal Blindness;Legal patent;legally blind;Libraries;liver function;macula;Macular degeneration;macular edema;Mammals;Marketing;Maximum Tolerated Dose;Medicine;multidisciplinary;neovascularization;new growth;next generation;No-Observed-Adverse-Effect Level;Nonexudative age-related macular degeneration;nonhuman primate;novel therapeutics;older adult;Ophthalmology;Oryctolagus cuniculus;Outcome;Pathway interactions;Patients;Persons;Phage Display;Pharmaceutical Preparations;Pharmacology;Phase;Phase I Clinical Trials;Population;pre-clinical;Pre-Clinical Model;Preclinical Drug Development;preclinical study;Productivity;programs;Property;Protein Engineering;Proteins;Quality Control;ranibizumab;Rattus;Renal function;Research Personnel;Retina;Retinal Diseases;Retinal Neovascularization;Retinal Vein Occlusion;Safety;Small Business Innovation Research Grant;Structure;Surgeon;surrogate light chain;Swelling;Syndrome;Therapeutic;therapeutic protein;Therapeutic Uses;Tissues;Toxic effect;Toxicology;Treatment Factor;Treatment Protocols;Vascular Diseases;Vascular Endothelial Growth Factor C;Vascular Endothelial Growth Factors;VEGFA gene;Visual Acuity;Western World

PROJECT_TITLE: Transformational next generation high affinity trispecific fab protein to address unmet needs in Ophthalmology

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-M (12)]


ADMINISTERING_IC: HL

ARRA_FUNDED: N

ED_INST_TYPE: SCHOOLS OF PUBLIC HEALTH

FUNDING_MECHANISM: NON-SBIR/STTR RPGS

IC_NAME: NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Childhood Obesity;Clinical Research;Mental Health;Nutrition;Obesity;Pediatric;Prevention

ORG_CITY: ANN ARBOR

ORG_COUNTRY: UNITED STATES

ORG_DEPT: PUBLIC HEALTH & PREV MEDICINE

ORG_FIPS: US

ORG_NAME: UNIVERSITY OF MICHIGAN AT ANN ARBOR

ORG_STATE: MI

PHR: PROJECT NARRATIVE Preventing obesity among young children is a public health priority. This study will identify how mothers' self- regulation, or their capacity to control emotions, thoughts, and behaviors, may impact their parenting and, in turn, their young children's growth. Findings will inform the development of new approaches to prevent and treat childhood obesity.

PI_NAMEs: BAUER, KATHERINE W. (contact)

PROGRAM_OFFICER_NAME: PRATT, CHARLOTTE A

PROJECT_TERMS: Address;Adherence;Adult;Age;Behavior;behavior change;Body mass index;Cardiovascular Diseases;Child;Child Rearing;Child Support;Cognition;community partnership;critical period;Data;Data Collection;Development;diabetes management;dyadic interaction;early childhood;Eating Disorders;Effectiveness of Interventions;Elements;emotion regulation;Emotions;Enrollment;Environment;executive function;experience;Family;family support;Food;Future;Goals;Growth;Health Promotion;Healthy Eating;healthy weight;improved;Individual;Informal Social Control;innovation;Insulin-Dependent Diabetes Mellitus;Intervention;Measures;Mediating;Methods;Mothers;novel;novel strategies;Obesity;obesity development;obesity in children;obesity prevention;obesity risk;obesity treatment;Outcome;parental role;Parents;Patient Self-Report;Positioning Attribute;prevent;Prospective, cohort study;public health priorities;Research;Resources;Risk;Risk Factors;Role;Sampling;Skinfold Thickness;Sleep;sociodemographics;success;Testing;therapy design;Thinking;United States National Institutes of Health;Vulnerable Populations;Weight;Weight maintenance regimen;Work

PROJECT_TITLE: Maternal Self-Regulation and Early Childhood Obesity

STUDY_SECTION: PRDP

STUDY_SECTION_NAME: Psychosocial Risk and Disease Prevention Study Section[PRDP]


ADMINISTERING_IC: GM

ED_INST_TYPE: SCHOOLS OF ARTS AND SCIENCES

IC_NAME: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

NIH_SPENDING_CATS: Women's Health Research

ORG_CITY: SANTA BARBARA

ORG_DEPT: BIOCHEMISTRY

ORG_NAME: UNIVERSITY OF CALIFORNIA SANTA BARBARA

ORG_STATE: CA

PHR: Relevance to public health Cell motility is a fundamental cell behavior that contributes to normal immune system function and is hijacked by cancer cells to spread, and we have developed a simple yet powerful animal model to study cell motility and engulfment (cells eating other cells). Our work has led to a novel understanding of a class of human immunodeficiencies and a novel strategy to improve cancer therapy. The current proposal is to uncover additional molecular mechanisms of cell motility and engulfment for the benefit of human health.

PI_NAMEs: MONTELL, DENISE J. (contact)

PROGRAM_OFFICER_NAME: WELLS, MELISSA LYNN

PROJECT_TERMS: Adhesives;Animal Model;Anterior;B-Lymphocytes;Basement membrane;cancer cell;cancer immunotherapy;cancer therapy;cell behavior;Cell Communication;cell killing;Cell model;cell motility;Cell Polarity;Cell Shape;cell type;Cells;Cellular Morphology;Chemicals;chronic infection;cohesion;Complex;congenital immunodeficiency;constitutive expression;Cytoskeleton;Development;Disease;Drosophila genus;Eating;egg;Epithelial Cells;Exhibits;Family;fly;follow-up;Funding;Genes;Genetic Models;Germ-Line Mutation;Goals;Guanosine Triphosphate Phosphohydrolases;Health;Hematopoietic;Human;human disease;Hyperactivity;Imaging Techniques;immune system function;immunodeficiency;improved;in vivo;in vivo Model;inhibitor;insight;Investigation;Macrophage;Mediating;migration;Molecular;Monomeric GTP-Binding Proteins;Mutation;Natural regeneration;Neoplasm Metastasis;Normal tissue morphology;novel;novel strategies;Nurses;Oocytes;Oogenesis;optogenetics;Ovary;Pathway interactions;Patients;Phagocytes;Phagocytosis;photoactivation;premature;Process;programs;Property;protein complex;Public Health;recruit;Regulation;rho;Role;Signal Transduction;spatiotemporal;Structure;Surface;System;T-Lymphocyte;Testing;tumor;Work

PROJECT_TITLE: Spatiotemporal regulation of collective cell behaviors in Drosophila

STUDY_SECTION_NAME: Development - 2 Study Section[DEV2]


ADMINISTERING_IC: AG

ED_INST_TYPE: SCHOOLS OF MEDICINE

FUNDING_MECHANISM: OTHER RESEARCH-RELATED

IC_NAME: NATIONAL INSTITUTE ON AGING

NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Biotechnology;Brain Disorders;Dementia;Genetics;Human Genome;Neurodegenerative;Neurosciences;Parkinson's Disease;Prevention;Stem Cell Research;Stem Cell Research - Induced Pluripotent Stem Cell;Stem Cell Research - Induced Pluripotent Stem Cell - Human;Stem Cell Research - Nonembryonic - Human

ORG_CITY: CHAPEL HILL

ORG_DEPT: INTERNAL MEDICINE/MEDICINE

ORG_NAME: UNIV OF NORTH CAROLINA CHAPEL HILL

ORG_STATE: NC

PHR: Parkinson’s disease (PD) is a common neurodegenerative condition with major impacts on quality of life, no disease-modifying therapy, and mechanistic links to the toxic accumulation of a particular protein. Mesenchymal stromal cells (MSCs) release molecules that help combat disease states, with the specific molecules released influenced by their environment and surrounding pathology. By comparing what MSCs release when in conditions simulating PD with what they secrete in normal conditions, we aim to identify molecules that could be used to therapeutically target the abnormally accumulating protein in Parkinson’s disease..

PI_NAMEs: BURGESS, JEREMY DANIEL (contact)

PROGRAM_OFFICER_NAME: ST  HILLAIRE-CLARKE, CORYSE

PROJECT_TERMS: Affect;Aging;alpha synuclein;Alzheimer's Disease;Alzheimer's disease risk;Biochemical;Biological Process;Brain;Caregivers;Cell model;Cell Physiology;cell type;Cells;Chemicals;Clinical Trials;combat;comparative;Complement;conditioning;cost;Data;Deterioration;Development;differential expression;Disease;disease model;Disease Progression;Disparate;Environment;Failure;Functional disorder;Gene Modified;Genes;Genetic;genetic association;Genetic Risk;genetic risk factor;genome wide association study;Goals;Health;Health Care Costs;Human;human subject;Immune;improved;induced pluripotent stem cell;Induced pluripotent stem cell derived neurons;interest;Lead;Link;Mediating;Mesenchymal Stem Cells;mesenchymal stromal cell;Modeling;multipotent cell;Nerve Degeneration;neural;Neurodegenerative Disorders;Neurofibrillary Tangles;neuron loss;Organoids;paracrine;Parkinson Disease;Pathogenesis;Pathologic;Pathology;Pathway interactions;Patients;Persons;Physiological;post-doctoral training;Postdoctoral Fellow;prevent;Property;Protein Secretion;Proteins;Proteomics;Quality of life;regenerative;Regenerative capacity;Research;Research Project Grants;risk variant;Rodent;Rotenone;Stains;Stimulus;symptom treatment;synucleinopathy;Techniques;Testing;Therapeutic Intervention;therapeutic target;Time;Tissues;Toxic effect;transcriptome;transcriptome sequencing;transcriptomics;Translating;Variant;Vascularization;Western Blotting

PROJECT_TITLE: Elucidating Immune and Microglial Dynamics in Alzheimer's Disease with Advanced Organoid Models.


ADMINISTERING_IC: HD

ED_INST_TYPE: BIOMED ENGR/COL ENGR/ENGR STA

IC_NAME: EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT

NIH_SPENDING_CATS: Bioengineering;Genetics;Human Genome

ORG_CITY: RICHARDSON

ORG_DEPT: BIOMEDICAL ENGINEERING

ORG_NAME: UNIVERSITY OF TEXAS DALLAS

ORG_STATE: TX

PHR: Project Narrative Despite the clear evidence between allelic effects and its influence on genetic architecture and disease risk, we lack comprehensive understanding of parental genetic inheritance and its regulation during development. This proposal aims to decode the dynamics and regulation of parental allelic expression at single-cell resolution, and answer the question that how the allelic imbalance contributes to normal and abnormal developmental process. It is expected that this data-rich approach will greatly enhance our understanding of embryonic development, and may serve as an important reference for studying patterns of disease inheritance.

PI_NAMEs: CAO, CHEN  (contact)

PROGRAM_OFFICER_NAME: STEIN, KATHRYN K

PROJECT_TERMS: 3-Dimensional;Alleles;Allelic Imbalance;Animals;ascidian;Bar Codes;Biological Assay;career development;Cell Count;Cell Lineage;cell type;Cells;Characteristics;Chromatin;Ciona intestinalis;Complex;Data;Development;Development Plans;Developmental Process;Dimensions;Disease;disorder risk;DNA Sequence;Embryo;Embryonic Development;Etiology;experimental study;Four-dimensional;Gene Expression;Genes;Genetic;genetic architecture;Genetic Diseases;Genetic Transcription;Genome;genome wide association study;Genomics;Haplotypes;Human;Hybrids;Individual;innovation;Interdisciplinary Study;Kinetics;Link;Maps;Measures;Mentorship;Methods;microscopic imaging;Morphogenesis;Neurons;novel strategies;Organ;Organism;Parents;Pattern;Phase;Population;Positioning Attribute;Process;programs;Rana;Regulation;Resolution;Role;single cell ATAC-seq;single cell sequencing;Single Nucleotide Polymorphism;single-cell RNA sequencing;Source;Specific qualifier value;Swimming;System;Tadpoles;Techniques;Technology;Time;Tissues;Training;transcriptome;transcriptomics;Variant;vertebrate embryos;Vertebrates;Work

PROJECT_TITLE: Decoding the dynamics and regulation of parental allelic expression at single-cell resolution

STUDY_SECTION: NSS

STUDY_SECTION_NAME: NSS


ADMINISTERING_IC: EY

FUNDING_MECHANISM: SBIR-STTR RPGS

IC_NAME: NATIONAL EYE INSTITUTE

NIH_SPENDING_CATS: Aging;Complementary and Integrative Health;Eye Disease and Disorders of Vision;Neurodegenerative;Neurosciences;Prevention

ORG_CITY: NAPERVILLE

ORG_NAME: HUMAN CELL CO

PHR: NARRATIVE  The efficacy and safety of combining topical nerve growth factor and oral vitamin B 3 supplement will be evaluated in a murine model of glaucoma.

PI_NAMEs: JEONG, SOON SEOG  (contact)

PROJECT_TERMS: Action Potentials;Age;Aging;Animal Model;Astrocytes;Attenuated;Axon;Axonal Transport;Binding;Blindness;Cauterize;Cell Energetics;Cell Physiology;Cell Survival;Cells;Characteristics;Clinical;Clinical Trials;cofactor;Combined Modality Therapy;Contrast Sensitivity;Corneal Ulcer;cost effective;design;Development;diabetic;Disease;disease model;Drug usage;Dry Eye Syndromes;efficacy validation;Electrophysiology (science);Enzymes;Experimental Models;Eye;eye dryness;FDA approved;Food Additives;Functional disorder;Generations;Glaucoma;Goals;Half-Life;Human;Immune;improved;Inflammation;inhibitor;innovation;Malignant Neoplasms;Mammalian Cell;Mediating;Metabolic stress;Microspheres;Mitochondria;mitochondrial dysfunction;Modeling;modifiable risk;Modification;mouse model;Mus;Nerve;Nerve Growth Factors;neuron apoptosis;neuronal cell body;neuronal growth;Neurons;neuropathology;Neurotrophic Keratitis;Neurotrophic Tyrosine Kinase Receptor Type 1;NGFR Protein;Niacinamide;nonhuman primate;novel therapeutics;Optic Nerve;Oral;oral supplementation;Oryctolagus cuniculus;Patient Recruitments;Patients;Persons;Pharmaceutical Preparations;Phase;phase 1 study;Physiologic Intraocular Pressure;Physiological;Population;pre-clinical;preservation;prevent;Process;Proteins;Rattus;receptor;Recombinants;repaired;Retina;retinal ganglion cell degeneration;Retinal Ganglion Cells;Risk Factors;Safety;Scotoma;Serum;side effect;Signal Transduction;Small Business Innovation Research Grant;success;Supplementation;Surface;Therapeutic Index;Time;Topical application;translation to humans;Veins;Vision;Visual;Visual Acuity;Visual Fields;Work

PROJECT_TITLE: Topical NGF Therapy and oral nicotinamide supplementation for Glaucoma


ADMINISTERING_IC: MH

IC_NAME: NATIONAL INSTITUTE OF MENTAL HEALTH

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Biomedical Imaging;Brain Disorders;Clinical Research;Depression;Mental Health;Mental Illness;Neurosciences;Pediatric;Serious Mental Illness

ORG_CITY: CORAL GABLES

ORG_DEPT: PSYCHIATRY

ORG_NAME: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE

ORG_STATE: FL

PHR: PROJECT NARRATIVE Our overall goal is to better understand the mechanisms contributing to the maintenance and severity of adolescent depression. A prospective multimodal study will test the overall hypothesis that reward dysfunction and associated neuroimmunological abnormalities contribute to depression progression in youth. Such work would provide information on modifiable factors to facilitate novel treatment approaches influencing the course of illness early on and prior to chronicity effects, so that we may work to ameliorate morbidity and mortality of this devastating disorder.

PI_NAMEs: GABBAY, VILMA  (contact)

PROGRAM_OFFICER_NAME: MURPHY, ERIC ROUSSEAU

PROJECT_TERMS: Accounting;Address;Adolescent;Adopted;Adult;age group;analytical method;Anhedonia;Anterior;Antioxidants;Anxiety;Behavioral;behavioral construct;biobehavior;Biological;Biological Markers;Blood;Brain;Brain region;causal model;Cause of Death;cell type;Cells;child depression;Chronic;cingulate cortex;Collection;computerized;Corpus striatum structure;cytokine;Data;Depressed mood;depressive symptoms;Development;Disease;Exhibits;experience;Family;follow-up;Functional Magnetic Resonance Imaging;Future;Gambling;gamma-Aminobutyric Acid;Glutathione;Goals;Heterogeneity;Hydrocortisone;Immune;Immunologic Stimulation;Immunologics;indexing;Individual Differences;Inflammation;Inflammatory;Investigation;Knowledge;Kynurenine;Laboratories;Learning;machine learning classification;Magnetic Resonance Spectroscopy;Maintenance;Maps;Marketing;Measures;Mediating;Mental Depression;Methods;Modeling;Morbidity - disease rate;mortality;multimodality;neural;neural circuit;neurochemistry;neuroimaging;Neuroimmune;Neuroimmunomodulation;Neurotransmitters;novel;Outcome;Outcome Measure;outcome prediction;Oxidative Stress Induction;Pathway interactions;Pattern;Peripheral;Pilot Projects;pleasure;primary outcome;Process;prospective;Prospective Studies;Protons;Puberty;Public Health;Reporting;research clinical testing;Research Domain Criteria;Rest;reward anticipation;reward circuitry;reward dysfunction;Rewards;Role;Severities;sex;Stress;stressor;subthreshold depression;suicidal;Suicide;Sum;Symptoms;Testing;Trauma;Visit;Work;Youth

PROJECT_TITLE: Biobehavioral Predictors of Illness Progression in Adolescent Depression

STUDY_SECTION: CPDD

STUDY_SECTION_NAME: Child Psychopathology and Developmental Disabilities Study Section[CPDD]


FUNDING_MECHANISM: RESEARCH CENTERS

ORG_CITY: CAMBRIDGE

ORG_NAME: NATIONAL BUREAU OF ECONOMIC RESEARCH

ORG_STATE: MA

PHR: OTHER PROJECT INFORMATION – Project Narrative NBER Coordinating Center on the Economics of AD/ADRD Prevention, Treatment, and Care There are many public health reasons for a coordinated research consortium on the economics of Alzheimer’s disease and Alzheimer’s related dementias. First, the rising prevalence of ADRD with an aging population represents a profound and emergent challenge to our health and long-term care systems. Second, we are poised for a dramatic acceleration in our understanding of how to prevent and treat ADRD. Third, there are unique aspects, potential barriers, and disparities in how healthcare systems provide healthcare to people with ADRD.

PI_NAMEs: AU, RHODA ;BYNUM, JULIE PW;MCGARRY, KATHLEEN  (contact)

PROGRAM_OFFICER_NAME: PHILLIPS, JOHN

PROJECT_TERMS: Acceleration;aging population;Alzheimer's Disease;Alzheimer's disease related dementia;Architecture;Attention;Award;base;care systems;career;Caregivers;caregiving;Caring;Collaborations;Communication;Communities;Companions;Country;Diagnosis;Economics;Educational workshop;Ensure;experience;Family;Fostering;Funding;Future;Goals;Grant;Health;health care disparity;health economics;Healthcare;Healthcare Systems;improved;Individual;Institution;Leadership;Long-Term Care;member;Mentors;Methods;Monitor;NIH Program Announcements;Patient Care;Performance;Personal Satisfaction;Persons;Policy Making;Prevalence;prevent;Prevention;Process;programs;Public Health;Recording of previous events;Research;Research Personnel;Research Priority;Research Project Grants;Research Support;Resources;Role;Scholars Program;Societies;Structure;success;symposium;synergism;translational impact;Translations;Universities;Washington;Work

PROJECT_TITLE: NBER Coordinating Center on the Economics of AD/ADRD Prevention, Treatment, and Care.

STUDY_SECTION_NAME: Special Emphasis Panel[ZAG1 ZIJ-8 (M4)]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Clinical Research;Dementia;Neurodegenerative;Neurosciences;Prevention

PI_NAMEs: MCGARRY, KATHLEEN  (contact)

PROJECT_TERMS: Alzheimer's disease related dementia;Attention;Businesses;career;Caring;Collaborations;Communication;Communities;Companions;Complex;data resource;Dimensions;Economics;Event;Human Resources;Leadership;Link;meetings;Monitor;Names;NIH Program Announcements;operation;outreach;Prevention;Process;Productivity;programs;Research;Research Personnel;Research Priority;Research Project Grants;Research Support;residence;Resource Sharing;Resources;Scholars Program;Site;Specific qualifier value;success;System;Technical Expertise;Touch sensation;Training;training opportunity;Translations;U-Series Cooperative Agreements;web site

PROJECT_TITLE: Administrative Core


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Brain Disorders;Clinical Research;Dementia;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurodegenerative;Neurosciences;Prevention

PROJECT_TERMS: Aging;Alzheimer's disease related dementia;Architecture;Area;Award;Budgets;caregiving;Caring;Companions;Consultations;cost;Dementia;Diagnosis;Economics;Evaluation Research;Funding;Goals;Grant;Health;health care disparity;Individual;Institution;Leadership;Modification;NIH Program Announcements;Patient Care;Peer Review;Persons;Prevention;Process;programs;Reporting;Research;Research Personnel;Research Priority;Research Project Grants;Resources;Structure;U-Series Cooperative Agreements;Work

PROJECT_TITLE: Research Project Core


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Behavioral and Social Science;Brain Disorders;Caregiving Research;Dementia;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurodegenerative;Neurosciences;Prevention;Social Determinants of Health

PI_NAMEs: BYNUM, JULIE PW (contact)

PROJECT_TERMS: Advocate;Ally;Alzheimer's Disease;Alzheimer's disease related dementia;care providers;Caregivers;caregiving;Caring;Categories;Code;Cognition;Collaborations;Data;data archive;Disparity;Economics;Educational workshop;experience;Family;Funding;Government Officials;Health;health care disparity;health equity promotion;Healthcare;improved;Infrastructure;insight;International;Measurement;Measures;Medicare;Medicare claim;meetings;Newsletter;Personal Satisfaction;Persons;Policy Maker;Prevention;Process;programs;Provider;Publishing;Reporting;Research;research data dissemination;Research Personnel;Resources;Review Literature;Risk Factors;Site;Social Sciences;symposium;translational goal;translational impact;Translations;Washington;Work;Writing

PROJECT_TITLE: Translation Core


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Behavioral and Social Science;Brain Disorders;Caregiving Research;Dementia;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Neurodegenerative;Neurosciences;Prevention

PI_NAMEs: AU, RHODA  (contact)

PROJECT_TERMS: Accountability;Advocacy;Alzheimer's disease related dementia;Appointment;Area;Biotechnology;Capital;Caregivers;caregiving;Caring;Categories;Communication;Communities;Dedications;drug development;Economics;Equity;experience;Family;Federal Government;Formal caregiver;Formal caregiving;Foundations;Geriatrics;Government Agencies;Health;health care disparity;health disparity;Healthcare;improved;Industry;informal caregiver;informal caregiving;Insurance;Learning;Long-Term Care;meetings;Monitor;Names;novel therapeutics;Persons;Pharmacologic Substance;Prevention;Privatization;Process;Provider;Research;Research Priority;Research Project Grants;Resource Sharing;State Government;Structure;Thinking;Time;translational impact;translational potential;Translations;web site;Work

PROJECT_TITLE: Stakeholder Engagement Core


ED_INST_TYPE: ORGANIZED RESEARCH UNITS

NIH_SPENDING_CATS: Cardiovascular;Heart Disease

ORG_CITY: BLACKSBURG

ORG_DEPT: MISCELLANEOUS

ORG_NAME: VIRGINIA POLYTECHNIC INST AND ST UNIV

ORG_STATE: VA

PHR: NARRATIVE The International Gap Junction Conference (IGJC) is a biannual international meeting that has been ongoing since 1987. This meeting is the only one of its kind that gathers scientists and clinicians from all over the world to present and discuss research on critical proteins that allow human cells to communicate with each other and the spaces around them. This is relevant to public health because there proteins are altered in almost all human disease states and research shared and collaborations forged at the meeting will contribute to development of therapies targeting heart disease, neurological disorders, and cancer; to name a few.

PI_NAMEs: SMYTH, JAMES WILLIAM (contact)

PROGRAM_OFFICER_NAME: TJURMINA, OLGA A

PROJECT_TERMS: Area;Arrhythmia;Award;Basic Science;bench to bedside;Biology;Biophysics;Blood;Blood Pressure;Blood Vessels;Cardiac;Cardiovascular system;career;Cell surface;Cells;Collaborations;Communication;Communities;Connexins;cost;Coupling;Dedications;Disabled Persons;Disease Progression;Educational workshop;Europe;Evolution;Exclusion;forging;Fostering;Funding;Gap Junctions;Genetic Transcription;Goals;Health;Heart;Heart Diseases;Human;human disease;insight;Intellectual Property;intercellular communication;interdisciplinary collaboration;International;Invertebrates;Lesbian Gay Bisexual Transgender Queer;Lung;Maintenance;Malignant Neoplasms;Mediating;meetings;model organism;Mutation;Myocardium;Names;National Heart, Lung, and Blood Institute;Nervous System Disorder;Normal Cell;Normal tissue morphology;Oral;Organ;Pathologic;Post-Translational Protein Processing;pre-clinical research;programs;Proteins;Protomer;Public Health;Recording of previous events;Regulation;Research;Research Personnel;Role;Running;Science;Scientist;Signal Transduction;Structure;success;sudden cardiac death;symposium;targeted treatment;Therapeutic;therapy development;Tissues;Translations;Travel;Virginia;Woman

PROJECT_TITLE: International Gap Junction Conference 2024

STUDY_SECTION_NAME: Special Emphasis Panel[ZHL1 CSR-O (M4)]


ADMINISTERING_IC: CA

IC_NAME: NATIONAL CANCER INSTITUTE

ORG_CITY: BUFFALO

ORG_NAME: ROSWELL PARK CANCER INSTITUTE CORP

ORG_STATE: NY

PHR: Project Narrative While several innovative and creative immuno-oncology (IO) strategies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate the resistance mechanism, discover new immune targets, identify predictive biomarkers, evaluate combination therapies, and develop preventive approaches. Utilizing a multi-disciplinary team approach, we will support Immuno-Oncology Translation Network (IOTN)-funded components to discover new immune targets and evaluate novel immune- based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur.

PI_NAMEs: HUTSON, ALAN DAVID (contact);LIU, SONG ;MORGAN, MARTIN T

PROGRAM_OFFICER_NAME: KUO, LILLIAN S

PROJECT_TERMS: Address;Adult;biobank;Bioconductor;Bioinformatics;biomedical data science;Biometry;Cancer Center Support Grant;Clinical;Collaborations;Combined Modality Therapy;Communities;community engagement;cost effective;Creativeness;data centers;Data Collection;Data Coordinating Center;data integration;data management;data repository;data sharing networks;design;experience;flexibility;Fostering;Funding;high standard;Immune;Immune Targeting;Immunooncology;Immunotherapy;improved;Infrastructure;innovation;Institution;Malignant Neoplasms;Methods;multidisciplinary;novel;Oncology;predictive marker;prevent;Preventive;Productivity;programs;Research;Research Personnel;resistance mechanism;Resource Sharing;Resources;Site;translational oncology;translational study

PROJECT_TITLE: Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

SUFFIX: SA


ADMINISTERING_IC: AI

IC_NAME: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

ORG_CITY: SAN FRANCISCO

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO

PI_NAMEs: ANDERSON, MARK S (contact)

PROGRAM_OFFICER_NAME: MORRIS FEARS, MARGARET A


PROJECT_TITLE: Core A:  Mouse Core


PI_NAMEs: MARSON, ALEXANDER  (contact)

PROJECT_TITLE: Core B:  Human Genetics and Genomics Core


PI_NAMEs: COOPER, MEGAN ANNE (contact)

PROJECT_TITLE: Project 1: Functional consequences of STAT3 GOF on immune cell signaling


PROJECT_TITLE: Project 2: STAT3 as a trigger for T1D


PROJECT_TITLE: Project 3: CRISPR Genome Editing to Understand and Correct STAT3 GOF Immune Dysregulation


ADMINISTERING_IC: ES

IC_NAME: NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES

NIH_SPENDING_CATS: Bioengineering;Data Science;Machine Learning and Artificial Intelligence;Networking and Information Technology R&D (NITRD);Neurosciences

ORG_CITY: FUQUAY VARINA

ORG_NAME: COLLABORATIONS PHARMACEUTICALS, INC.

PHR: Narrative There are nearly 3 million poisonings per year with organophosphates resulting in three hundred thousand deaths (at least 8000 in the US alone). We have used a combination of high throughput screening and machine learning to identify compounds that inhibit acetylcholinesterase (AChE) as well as used software to autocurate available literature data on AChE from human and other species in order to build and validate machine learning models. We have also recently used contrastive learning to prospectively identify several new selective butyrylcholinesterase (BChE) inhibitors after scoring a library of 5 million molecules. In Phase II we will develop the MegaAChE software product for prediction of AChE inhibition to identify potential molecules that bind to AChE in order to predict pesticide and nerve agent poisoning across species and incorporate new validated models with a specific focus on developing novel AChE reactivators for treating pesticide and nerve agent exposure. This proposal will develop both software and molecule intellectual property which we can ultimately license to larger customers across several industries (agrochemical, pharmaceutical, environmental and defense) to create revenue for our small but growing company.

PI_NAMEs: EKINS, SEAN  (contact)

PROGRAM_OFFICER_NAME: RAVICHANDRAN, LINGAMANAIDU V

PROJECT_TERMS: Acetylcholine;Acetylcholinesterase;Acetylcholinesterase Inhibitors;Adverse effects;Affect;Agrochemicals;Algorithms;Alzheimer's Disease;Amphibia;analog;Awareness;Bayesian Modeling;Binding;Biological;Biological Assay;Blood - brain barrier anatomy;blood-brain barrier crossing;Brain;Butyrylcholinesterase;Cessation of life;cholinergic synapse;Computer Models;Computer software;Data;Data Set;design;Diameter;drug discovery;Eels;Environment;Enzymes;experience;experimental study;Exposure to;Fingerprint;Fishes;Goals;Grant;high throughput screening;Human;Hybrids;In Vitro;in vitro activity;in vitro testing;Individual;Industry;inhibitor;Intellectual Property;large language model;Learning;learning algorithm;Libraries;Licensing;Literature;Machine Learning;machine learning algorithm;machine learning framework;machine learning model;machine learning prediction;Measurement;Methodology;Modeling;Molecular;Muscarinic Acetylcholine Receptor;nerve agent;neural;Neuromuscular Junction;Neurons;Nicotinic Receptors;novel;Organism;Organophosphates;Organophosphorus Compounds;Output;Patients;Performance;Pesticides;Pharmaceutical Preparations;Pharmacologic Substance;Phase;Poison;Poisoning;predictive modeling;Process;prospective;public database;Publications;Receiver Operating Characteristics;Small Business Innovation Research Grant;small molecule;Software Design;software development;Source;Techniques;Testing;Therapeutic;tool;Toxic effect;Training;transfer learning;Uncertainty;Validation;Vendor;virtual screening;Work

PROJECT_TITLE: Machine learning approaches to predict Acetylcholinesterase inhibition and model applications

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-B (14)]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Behavioral and Social Science;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Dementia;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Health Services;Neurodegenerative;Social Determinants of Health

ORG_CITY: MINNEAPOLIS

ORG_NAME: UNIVERSITY OF MINNESOTA

ORG_STATE: MN

PHR: Narrative: This study is designed to help improve the care of SGM with AD/ADRD in LTSS by conducting a rigorous study of the policies of LTSS agencies in Minnesota and by training the state’s LTSS workforce in SGM culturally responsive care. The study of policy will inform whether LTSS agencies need regulation or have already adopted SGM appropriate policies. The randomized controlled trial will rigorously test the effects of an in-person versus an online training program on improving SGM culturally responsive care.

PI_NAMEs: ROSSER, B R SIMON  (contact);SHIPPEE, TETYANA P.

PROGRAM_OFFICER_NAME: GERALD, MELISSA S

PROJECT_TERMS: Address;Adopted;Alzheimer's disease related dementia;Alzheimer's disease risk;arm;Assisted Living Facilities;Attitude;Caring;cisgender;Client;comparative effectiveness study;Control Groups;Data Collection;dementia care;design;Discrimination;Educational Curriculum;Environment;evidence base;follow-up;Gender Identity;Health;Heterosexuals;Human Resources;improved;Individual;Inferior;Instruction;Intake;Knowledge;Long-Term Care;Marketing;Methods;Minnesota;Nursing Homes;older adult;online course;online version;Outcome;peer;Persons;Policies;Policy Analysis;Quality of life;Randomized, Controlled Trials;Regulation;Research;Services;Sex Orientation;Sexual and Gender Minorities;skills;Statutes and Laws;Testing;Training;Training Programs;Waiting Lists

PROJECT_TITLE: Training the Long-Term Services and Supports Dementia Care Workforce in Provision of Care to Sexual and Gender Minority Residents

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1(02)]


ADMINISTERING_IC: AT

IC_NAME: NATIONAL CENTER FOR COMPLEMENTARY & INTEGRATIVE HEALTH

NIH_SPENDING_CATS: Behavioral and Social Science;Biomedical Imaging;Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Complementary and Integrative Health;Depression;Machine Learning and Artificial Intelligence;Mental Health;Mental Illness;Neurosciences;Pediatric;Prevention

ORG_CITY: BELMONT

ORG_NAME: MCLEAN HOSPITAL

PHR: Project Narrative Rumination is a transdiagnostic risk factor for developing depression and anxiety in adolescents. Rumination is fundamentally a maladaptive mental process in response to stressors in life. Through analyzing the baseline multimodal data collected from the parent R01, the proposed project will identify significant brain areas with gray matter density, spontaneous brain activity or resting state functional connectivity associated with adolescents’ trait rumination characteristics and inhibitory control capabilities.

PI_NAMEs: JOSS, DIANE ;WEBB, CHRISTIAN ANTHONY (contact)

PROGRAM_OFFICER_NAME: QUINLAN, ERIN BURKE

PROJECT_TERMS: Administrative Supplement;Adolescent;adolescent mental health;Algorithms;Amygdaloid structure;Anatomy;Anterior;Anxiety;Applications Grants;Area;Area Under Curve;Brain;center for epidemiological studies depression scale;Characteristics;Child Abuse and Neglect;child depression;cingulate cortex;Clinical;clinical practice;Cognitive;Data;density;depressive symptoms;design;Diagnostic;Dorsal;Ecological momentary assessment;experience;Failure;feature selection;Female Adolescents;Frequencies;Functional Magnetic Resonance Imaging;gray matter;Hippocampus;Individual;individual variation;interest;Intervention;Knowledge;Lateral;Left;Life;Linear Regressions;Machine Learning;Magnetic Resonance Imaging;Maps;Masks;Measurement;Measures;Medial;Mental Depression;Mental Processes;Mind;Mindfulness Training;mobile application;Modeling;morphometry;multimodal data;multimodality;National Institute of Mental Health;neural;neural correlate;Neurobiology;operation;parent grant;Parents;Parietal;Performance;personalized predictions;predicting response;Prediction of Response to Therapy;Prefrontal Cortex;prevent;prevention practice;Prevention program;Probability;Process;psychologic;Recording of previous events;Regression Analysis;Research;Research Project Grants;response;Rest;Risk Factors;rumination;Series;Severities;stressor;sustained attention;Task Performances;Testing;Thinking;Time;trait;treatment response;Validation

PROJECT_TITLE: Supplemental: Neural and cognitive propensity for trait rumination in adolescents: a multimodal study with ecological momentary assessments and MRI

STUDY_SECTION: MESH

STUDY_SECTION_NAME: Biobehavioral Mechanisms of Emotion, Stress and Health Study Section[MESH]


NIH_SPENDING_CATS: Cancer;Childhood Leukemia;Clinical Research;Clinical Trials and Supportive Activities;Hematology;Neuroblastoma;Neurosciences;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: OAKLAND

ORG_NAME: PUBLIC HEALTH INSTITUTE

PHR: PROJECT NARRATIVE The Children’s Oncology Group (COG) is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. Over 220 leading children’s hospitals, universities, and cancer centers across US, Canada and other countries participate in COG research, which is focused on developing better treatments that can improve the cure rate and outcomes for all children with cancer.

PI_NAMEs: HAWKINS, DOUGLAS S. (contact)

PROGRAM_OFFICER_NAME: MOONEY, MARGARET M

PROJECT_TERMS: 1 year old;Acceleration;Acute Myelocytic Leukemia;Adolescent;anti-cancer research;Brain Stem Glioma;Canada;Cancer Center;cancer therapy;Cause of Death;Cell Therapy;chemotherapy;Child;Child Support;Childhood;childhood cancer survivor;Childhood Leukemia;Clinical;clinical translation;Clinical Trials;Clinical Trials Design;Collection;Complication;Country;design;Development;Diagnosis;Disease;Eligibility Determination;Enrollment;experience;Family;Foundations;Functional disorder;health related quality of life;high risk;Hormonal;Immunotherapy;improved;improved outcome;innovation;Institution;Interdisciplinary Study;Laboratories;Late Effects;Malignant Childhood Neoplasm;Malignant Neoplasms;member;Mission;Molecular;National Cancer Institute;National Clinical Trials Network;Neuroblastoma;novel therapeutic intervention;operation;Organ;Outcome;Pediatric Hospitals;Pediatric Oncology Group;Pharmaceutical Preparations;Population Heterogeneity;Prognosis;Progress Reports;Quality of life;Rare Diseases;reproductive;Research;Research Personnel;Scientist;Second Primary Cancers;Site;small molecule;Survival Rate;Tissues;translational study;Universities;Work

PROJECT_TITLE: COG NCTN Year 11 BIQSFP Progress Report


FUNDING_MECHANISM: TRAINING, INDIVIDUAL

NIH_SPENDING_CATS: Bioengineering;Cardiovascular;Clinical Research;Congenital Heart Disease;Congenital Structural Anomalies;Heart Disease;Infant Mortality;Pediatric;Physical Activity;Pulmonary Hypertension;Rare Diseases

ORG_CITY: LA JOLLA

ORG_DEPT: ENGINEERING (ALL TYPES)

ORG_NAME: UNIVERSITY OF CALIFORNIA, SAN DIEGO

PHR: Project Narrative Residual and progressive ventricular dysfunction is common in adult survivors of repaired tetralogy of Fallot (rTOF), and conventional functional assessments reflect late-stage dysfunction that poorly predicts clinical outcomes. This proposal aims to investigate regions of subclinical right ventricular dysfunction in adult patients with rTOF using a CT-based approach. Detection of subclinical dysfunction with CT will improve long-term management of adults with rTOF by increasing accessibility to imaging-based functional assessment and characterizing impairment early and robustly, thus leading to more informed clinical decision-making.

PI_NAMEs: CRAINE, AMANDA  (contact)

PROGRAM_OFFICER_NAME: LIDMAN, KARIN FREDRIKSSON

PROJECT_TERMS: Adult;Age Years;Agreement;Anatomy;Area;Arrhythmia;Cardiac;Cardiopulmonary;Caring;Categories;Clinical;clinical care;clinical decision-making;Clinical Management;Complex;Complication;congenital heart abnormality;Cross-Sectional Studies;Cyanotic heart disease;Data;Detection;Deterioration;Dose;Early Diagnosis;Electrocardiogram;Elements;Endocardium;Evaluation;Event;Exercise Test;Exercise Tolerance;experience;follow-up;Functional disorder;Geometry;Global Change;Goals;Heart failure;Heterogeneity;Image;Impairment;implantable device;improved;Life;Longitudinal Studies;Maps;Measurement;Measures;Methods;Modeling;Myocardial;Myocardial dysfunction;Myocardial perfusion;Operative Surgical Procedures;Outcome;Patients;Performance;Physiologic intraventricular pressure;Population;predict clinical outcome;preservation;pressure;Quality of life;regional difference;repaired;Residual state;Resolution;Right Ventricular Dysfunction;Right Ventricular Function;Risk;Stress;sudden cardiac death;Survivors;symptomatology;Techniques;Tetralogy of Fallot;Therapeutic;tool;Variant;Ventricular;Ventricular Dysfunction;Visualization;Work;X-Ray Computed Tomography

PROJECT_TITLE: High spatial resolution evaluation of subclinical regions of myocardial dysfunction in adult patients with tetralogy of Fallot


ED_INST_TYPE: UNIVERSITY-WIDE

NIH_SPENDING_CATS: Cachexia;Cancer;Cardiovascular;Digestive Diseases;Heart Disease;Neurosciences;Nutrition;Pancreatic Cancer;Rare Diseases

ORG_CITY: PORTLAND

ORG_NAME: OREGON HEALTH & SCIENCE UNIVERSITY

ORG_STATE: OR

PHR: Project Narrative Cachexia is a devastating and often fatal complication of many illnesses, with signs and symptoms including loss of appetite, muscle breakdown, and a weak heart. The impairment in heart function reduces quality of life and also severely limits the treatment options for patients, yet the mechanisms underlying cancer-cachexia associated heart disease are poorly understood. This project explores a novel mechanism of heart damage in cancer cachexia, whereby an elevated fight-or-flight response regulates dysfunctional reprogramming of the heart as well as immune cell infiltration into the heart.

PI_NAMEs: DIBA, PARHAM  (contact)

PROGRAM_OFFICER_NAME: MEADOWS, TAWANNA

PROJECT_TERMS: Acquired Immunodeficiency Syndrome;Adipose tissue;Adrenergic Agents;Adrenergic Antagonists;Adrenergic beta-Antagonists;Adrenergic Receptor;Affect;Animal Cancer Model;Animal Model;Animals;Anorexia;antibody conjugate;appetite loss;Atrophic;Attenuated;Automobile Driving;Basal metabolic rate;Biological Markers;Blood;Body Weight decreased;Bone Marrow;Cachexia;Calcium;Cancer Cachexia;Cancer Model;Cancer Patient;cancer therapy;Cardiac;Cardiac Myocytes;Cardiovascular Pathology;Cardiovascular system;Cells;Cessation of life;Chemical Sympathectomy;chemotherapeutic agent;chemotherapy;Chronic;Chronic Disease;Cirrhosis;Clinical;Colony-Forming Units Assay;comorbidity;Complication;coronary fibrosis;Data;desensitization;Desire for food;Development;Disease;Dopamine-beta-monooxygenase;Down-Regulation;effective therapy;EFRAC;Enhancers;Evolution;extracellular;Extravasation;Fatigue;Fibrosis;fighting;Flow Cytometry;Functional disorder;Ganglia;Genetic;genetic signature;Goals;Heart;heart damage;Heart Diseases;Heart failure;heart function;Heart Neoplasms;Heart Rate;heart rate variability;Homeostasis;Hyperactivity;Immune;immune cell infiltrate;Impairment;improved;Individual;Inflammation;Inflammatory;Injections;Kidney Failure;Left;Leukocytes;lipid metabolism;Literature;Malignant Neoplasms;Malnutrition;Measures;Mediating;Mediator;metabolic rate;Modeling;Molecular;Mus;Muscular Atrophy;Myelopoiesis;Myocardial;Myocardial Degeneration;Myocardial dysfunction;Myosin ATPase;Myosin Heavy Chains;Nerve;neutrophil;Neutrophil Infiltration;new therapeutic target;Norepinephrine;novel;Organ;Pancreatic Ductal Adenocarcinoma;pancreatic ductal adenocarcinoma model;Pathology;Pathway interactions;Patients;Peptide Hydrolases;Pericardial body location;Population;Prevention;Production;Prognosis;Protein Isoforms;Quality of life;Receptors, Adrenergic, beta-3;recruit;response;Rest;reuptake;Role;Signal Transduction;Signs and Symptoms;Stress;Stromal Cell-Derived Factor 1;Structure of postganglionic sympathetic fiber;Sympathetic Nervous System;Symptoms;Therapeutic;Thinness;Time;Tissues;Toxin;transcription factor;Treatment Efficacy;tumor progression;Ventricular;wasting;Wasting Syndrome;Work

PROJECT_TITLE: The role of adrenergic signaling in cancer cachexia-associated cardiac remodeling


ADMINISTERING_IC: DC

IC_NAME: NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS

NIH_SPENDING_CATS: Hearing Loss;Neurosciences;Prevention

ORG_NAME: JACARANDA BIOSCIENCES, INC.

PHR: Narrative: In this Phase 1 SBIR, we propose to use the knowledge gained in our initial phase 1 grant to devise a new range of novel highly efficacious compounds that will be targeted to the unfolded protein response. These will aim to specifically prevent cisplatin ototoxicity/hearing loss in patients undergoing treatment for a broad range of solid tumors. These compounds will target the eif2B decamer within the UPR pathway and the study design will enable us to optimize in vitro and preclinical in vivo effectiveness with lack of toxicity.

PI_NAMEs: CHOUCHANE, MALEK  (contact);DAHL, RUSSELL

PROGRAM_OFFICER_NAME: MILLER, ROGER

PROJECT_TERMS: absorption;Address;Animal Model;anti-cancer;antioxidant enzyme;antitumor effect;Apoptosis;Apoptotic;arm;Auditory Brainstem Responses;Binding;Biological Assay;Biological Sciences;Biology;Cell Death;Cell Line;Cells;Cellular biology;Chemistry;Cisplatin;Cochlea;cytotoxicity;Data;design;Development;Dose Limiting;drug candidate;Drug Design;drug development;Drug Kinetics;Effectiveness;Endoplasmic Reticulum;Evaluation;Excretory function;FDA approved;first-in-human;Genetic;Goals;Government;Grant;Hair Cells;Hearing;hearing impairment;hearing loss treatment;hearing range;Hearing Tests;hereditary hearing loss;Immunohistochemistry;In Vitro;in vivo;in vivo evaluation;Induction of Apoptosis;inhibitor;Injury;innovation;insight;intraperitoneal;Knowledge;lead optimization;Metabolism;Modeling;Modification;Molecular;mouse model;Mus;nephrotoxicity;neurotoxicity;Noise;Noise-Induced Hearing Loss;novel;ototoxicity;Outcome Measure;Pathway interactions;Patients;Pharmaceutical Chemistry;Pharmaceutical Preparations;Pharmacodynamics;pharmacologic;Phase;Physiology;pre-clinical;prevent;prevent hearing loss;Property;Proteins;Publishing;Reactive Oxygen Species;Regulation;Research Design;response;Rodent;Secure;Series;side effect;Small Business Innovation Research Grant;sodium thiosulfate;Solid Neoplasm;Structure;Sulfur;targeted treatment;Testing;Therapeutic;Toxic effect;Toxicology;treatment trial;Western Blotting;Work

PROJECT_TITLE: Development of UPR-Targeted Treatment for Cisplatin-Induced Ototoxicity.


NIH_SPENDING_CATS: Machine Learning and Artificial Intelligence;Mental Health;Neurosciences;Orphan Drug;Rare Diseases

ORG_CITY: Paramus

ORG_NAME: PSYCHOGENICS, INC.

ORG_STATE: NJ

PHR: PROJECT NARRATIVE There is a great unmet need to repurpose already approved drugs for rare disorders as success rate in drug discovery has a high rate of failure, is costly and a slow process. In addition, drug companies may not have good incentive to take such a risky approach to drug development for the 90% of rare diseases that have no approved therapeutic treatment. Given the need to address repurposing in an efficient and systematic manner, PsychoGenics Inc. will develop a novel machine learning-based statistical approach to drug repurposing that can identify compounds and predict their phenotypic therapeutic potential for a portfolio of different rare disorders (at once) to guide the early stages of drug validation and translation to the clinic.

PI_NAMEs: BRUNNER, DANIELA  (contact)

PROGRAM_OFFICER_NAME: ANDERSON, PAIGE MARIE

PROJECT_TERMS: Address;Age;Algorithmic Analysis;Algorithms;Animal Disease Models;Animal Model;Attention deficit hyperactivity disorder;Behavioral;behavioral phenotyping;Brain;Breeding;Client;Clinic;Cognition;commercialization readiness;Complex;cost;Data;data mining;Data Set;Databases;Development;Disease;disease model;disease phenotype;donepezil;Dose;drug candidate;drug development;drug discovery;drug efficacy;drug repurposing;Drug Screening;Drug usage;Electroencephalography;Enhancers;Ensure;Failure;Fee-for-Service Plans;Galantamine;Genomics;Goals;Greek;Hand;high risk;improved;in vivo;in vivo evaluation;Incentives;innovation;interest;Investments;Linear Models;Literature;Machine Learning;machine learning model;Marketing;Mental disorders;Methods;Mind;MK801;model development;Modeling;Molecular;mouse model;Mus;Muscarinics;Names;neuropsychiatric disorder;novel;novel therapeutics;Pathology;Pathway interactions;Patients;Pharmaceutical Preparations;Phase;Phenotype;pre-clinical;Process;Rare Diseases;Safety;Scopolamine;screening;Sleep;success;Symptoms;System;Testing;Therapeutic;Time;Translations;Validation;Wild Type Mouse;xanomeline

PROJECT_TITLE: EEG Signature Analysis for Drug Repurposing for Rare Diseases

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-C (10)]


NIH_SPENDING_CATS: Cancer;Neuroblastoma;Neurosciences;Orphan Drug;Pediatric;Pediatric Cancer;Rare Diseases

ORG_CITY: RENSSELAER

ORG_NAME: NANOPHARMACEUTICALS, LLC

PHR: NARRATIVE: Neuroblastoma is the most common cancer diagnosed in children younger than one year of age and, for those with high-risk disease, results in only a 40-50% survival rate. Despite progress in treatment for the disease, survival rates have remained relatively unchanged. NanoPharmaceuticals LLC proposes a novel treatment for high-risk neuroblastoma using a drug-drug conjugate that binds to two highly expressed targets in neuroblastoma tumors, thereby providing the potential for improving survival in children suffering from this disease.

PI_NAMEs: DAVIS, PAUL  (contact)

PROGRAM_OFFICER_NAME: DJEMIL, SARRA

PROJECT_TERMS: 1 year old;5 year old;Admission activity;Adrenal Glands;Adrenergic Agents;Affinity;Age;analog;Angiogenesis Inhibitors;antagonist;anti-cancer;antiangiogenesis therapy;Apoptosis;Azoles;Bacterial Infections;Beds;BHLH Protein;Binding;Binding Proteins;Biology;cancer cell;cancer diagnosis;Cardiovascular system;Cell Line;Cell membrane;Central Nervous System;Chemicals;chemotherapy;Child;Classification;Clinical Trials;clinically relevant;Cytochromes;Development;Diagnosis;Disease;disorder risk;Dose;Drug Formulations;Drug Kinetics;Drug usage;efficacy evaluation;Evaluation;Excision;Face;Family;Fever;first-in-human;Formulation;Gene Amplification;Goals;High Dose Chemotherapy;high risk;High-Risk Cancer;Histopathology;I131 isotope;Image;Immunotherapy;Implant;improved;In Vitro;in vivo;in vivo evaluation;Integrin alphaVbeta3;Integrin Binding;International;irradiation;Kinetics;Label;Ligands;Malignant Childhood Neoplasm;Malignant Neoplasms;manufacture;manufacturing scale-up;Marrow;Measures;Mediating;Membrane Proteins;Metabolic;metaiodobenzylguanidine;Methods;Miniature Swine;Modality;Mus;MYCN gene;Mycoses;nanodrug;neoplastic cell;Neuroblastic Tumor;Neuroblastoma;neuroblastoma cell;neuroendocrine cancer;Neuroendocrine Cell;Neurons;Neutropenia;noradrenaline transporter;Norepinephrine;Normal Cell;novel;novel therapeutic intervention;Operative Surgical Procedures;Patients;PECAM1 gene;Pediatric Neoplasm;pediatric patients;Peripheral;Pharmaceutical Preparations;Phase;Phosphate Buffer;Polyethylene Glycols;pre-clinical;preclinical safety;Preparation;Primary Neoplasm;Process;Production;Prognosis;Proliferating;Property;Proto-Oncogenes;Qualifying;Radiosensitization;receptor;Reference Standards;respiratory;Retrospective Studies;Risk;Rodent;Safety;safety assessment;Saline;scale up;Small Business Innovation Research Grant;Solid Neoplasm;Solubility;standard care;Stem cell transplant;Surface;Survival Rate;Sympathetic Nervous System;Therapeutic;Thyroxine;Time;Toxic effect;Toxicokinetics;Toxicology;Treatment Efficacy;Treatment Protocols;tumor;tumor growth;tumor specificity;uptake;Validation;Variant;Xenograft procedure

PROJECT_TITLE: NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CTH-E (11)]


NIH_SPENDING_CATS: Attention Deficit Hyperactivity Disorder (ADHD);Behavioral and Social Science;Brain Disorders;Cardiovascular;Clinical Research;Clinical Trials and Supportive Activities;Congenital Heart Disease;Congenital Structural Anomalies;Disability Research;Down Syndrome;Heart Disease;Intellectual and Developmental Disabilities (IDD);Mental Health;Orphan Drug;Pediatric;Rare Diseases;Stimulant Use and Misuse

ORG_CITY: CINCINNATI

ORG_NAME: CINCINNATI CHILDRENS HOSP MED CTR

ORG_STATE: OH

PHR: PROJECT NARRATIVE Though children with Down syndrome (DS) are at increased risk for having a comorbid diagnosis of Attention- Deficit / Hyperactivity Disorder (ADHD), ADHD is often under-recognized in children with DS due to “diagnostic overshadowing” by the primary intellectual disability. Even when ADHD is diagnosed in children with DS, ADHD is often under-treated due to a lack of data to support the efficacy and safety of stimulant medication in children with DS+ADHD, especially among the 50% of children with DS who have congenital heart defects and for whom there could be increased cardiac risk. This study, the first clinical trial of stimulant medication in children with DS+ADHD, will determine the short- and long-term efficacy and safety of these medications in children with DS+ADHD and thus has the potential to significantly improve the functional status, behavior, and quality of life of children with DS+ADHD.

PI_NAMEs: ESBENSEN, ANNA J. (contact);FROEHLICH, TANYA E.

PROGRAM_OFFICER_NAME: BARDHAN, SUJATA

PROJECT_TERMS: Academic achievement;accurate diagnosis;Address;Adverse effects;aged;Area;Attention deficit hyperactivity disorder;Attenuated;Behavior;Behavioral;behavioral impairment;behavioral phenotyping;Cardiac;Catecholamines;Child;Clinical;Clinical Trials;clinically relevant;Cognitive;Cognitive remediation;comorbidity;Conduct Clinical Trials;congenital heart abnormality;Congenital Heart Defects;Consensus;Data;Defect;Developmental Disabilities;Diagnosis;Diagnostic;diagnostic criteria;Differential Diagnosis;Disease;Dose;Double-Blind Method;Down's Syndrome;Electrocardiogram;Enrollment;evidence based guidelines;executive function;Functional impairment;functional status;General Population;Genetic Diseases;Genotype;Goals;Guidelines;heart defect;Heart Diseases;heart function;high risk;Hyperactivity;Impaired cognition;Impairment;improved;improved outcome;Impulsivity;inattention;Incidence;Intellectual functioning disability;Language;Longterm Follow-up;medication safety;Monitor;Motor;neurophysiology;Outcome;Outcome Measure;Pharmaceutical Preparations;Pharmacotherapy;Phase;pilot trial;Placebos;Population;Prevalence;Protocols documentation;Provider;Quality of life;Randomized;randomized, clinical trials;Recommendation;Research;response;Risk;Ritalin;Safety;Sample Size;side effect;Stimulant;stimulant use;Symptoms;Treatment Efficacy;treatment strategy;Uncertainty;Underserved Population;Update;Vulnerable Populations

PROJECT_TITLE: Evaluating Assessment and Medication Treatment of ADHD in Children with Down Syndrome


FUNDING_MECHANISM: OTHERS

ORG_CITY: BOSTON

ORG_NAME: MASSACHUSETTS GENERAL HOSPITAL

PHR: No PHR

PI_NAMEs: FOULKES, ANDREA S (contact);KARLSON, ELIZABETH W;MURPHY, SHAWN N

PROGRAM_OFFICER_NAME: EBERT, RAY F

PROJECT_TERMS: analytical tool;cohort;data portal;Post-Acute Sequelae of SARS-CoV-2 Infection

PROJECT_TITLE: Interactive Data Portals and Robust Analytic Tools to Wrap PASC Cohorts (iDRAW) OTA-21-015A


ADMINISTERING_IC: EB

IC_NAME: NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING

NIH_SPENDING_CATS: Bioengineering;Biomedical Imaging;Networking and Information Technology R&D (NITRD);Neurosciences

ORG_CITY: BILLERICA

ORG_NAME: RESONANCE RESEARCH, INC.

PHR: Project Narrative Modern magnetic resonance imaging (MRI) techniques such as: functional magnetic resonance imaging (fMRI), white matter connectivity (tractography), susceptibility weighted imaging, CEST, and magnetic resonance spectroscopic imaging (MRSI) can benefit from accelerated data acquisition rates, parallel multi-band (MB) techniques and decreased distortion. Even the best shimming algorithms are subject to hardware limitations due to insufficient spatial frequency coverage, lack of strength and inability to perform dynamic shimming MB operations. In this work we are describing an agile, strong, true harmonic, very high order shim (VHOS) capable of generating a 4th order spherical harmonic shim (SH) that in combination with real-time, dynamic, techniques that can be used for acceleration of data acquisition rates through optimized MB shimming resulting in image quality improvements.

PI_NAMEs: STAREWICZ, PIOTR  (contact)

PROGRAM_OFFICER_NAME: ASHMONT, KARI RICH

PROJECT_TERMS: Acceleration;Algorithms;Amplifiers;anatomic imaging;Architecture;Body System;Brain;Brain region;Buffers;commercialization;Communication;Compensation;Computer software;cost;Coupled;Coupling;Data;data acquisition;Databases;Deposition;design;Development;digital;Disparate;Drops;Echo-Planar Imaging;Ensure;Evaluation;Feedback;Fiber Optics;flexibility;Frequencies;Functional Magnetic Resonance Imaging;Generations;Goals;Head;Human;Image;Imaging Techniques;improved;Individual;Length;Location;Magnetic Resonance Imaging;magnetic resonance spectroscopic imaging;Maps;Measurement;Medical;Methods;Modernization;Morphologic artifacts;Neck;neuroimaging;operation;Pattern;Performance;Phase;Positioning Attribute;Power Sources;Predisposition;printed circuit board;prototype;radio frequency;Ramp;Resistance;Resolution;Series;Shoulder;simulation;Slice;Source;Spectrum Analysis;Speed;Supervision;System;Techniques;Technology;Time;tractography;transmission process;Update;Vendor;white matter;Work

PROJECT_TITLE: Dynamic High-Order Shim System for Improved Neuro-MRI

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 ISB-Z (10)]


ADMINISTERING_IC: HG

IC_NAME: NATIONAL HUMAN GENOME RESEARCH INSTITUTE

NIH_SPENDING_CATS: Biotechnology;Genetics;Human Genome

ORG_CITY: Research Triangle Park

ORG_NAME: EPICYPHER, INC.

PHR: PROJECT NARRATIVE  Genomic mapping of histone post-translational modifications and chromatin-associated proteins is a powerful approach to unlock new clinical insights, including biomarker discovery and drug development. Despite this, there is a lack of high-quality approaches to perform genomic mapping in formalin-fixed paraffin-embedded (FFPE) clinical samples, millions of which are banked annually. Here, EpiCypher is developing CUTANA- FFPE™, a revolutionary assay that will enable genomic mapping in FFPE tissue and shed light on unexplored areas of clinical research that are beyond the reach of current technologies.

PI_NAMEs: KEOGH, MICHAEL-CHRISTOPHER  (contact)

PROGRAM_OFFICER_NAME: MORRIS, STEPHANIE A

PROJECT_TERMS: Antibodies;Area;Bioinformatics;Biological Assay;biomarker discovery;Cell Physiology;Chromatin;Cleavage Under Targets and Release Using Nuclease;Clinical;clinical application;Clinical Research;commercial launch;commercialization;cyanine dye 5;Data;data analysis pipeline;data integration;Development;Disease;DNA Damage;drug development;Ensure;Enzymes;Epigenetic Process;epigenomic profiling;epigenomics;Epitopes;Formalin;Fred Hutchinson Cancer Research Center;Freezing;genomic tools;Genomics;Goals;Gold;Health;Health Insurance Portability and Accountability Act;Histones;improved;In Situ;innovation;insight;Location;Manuals;Maps;Marketing;Methods;new technology;new therapeutic target;next generation;novel;novel marker;Paraffin Embedding;Pathology;Performance;Phase;Post-Translational Protein Processing;preservation;Procedures;Process;programs;Proteins;Quality Control;Regulation;Regulatory Element;Reproducibility;Research;Resolution;Retrieval;Sampling;Services;Signal Transduction;Slide;Sodium Chloride;Technology;therapeutic target;Tissue Embedding;Tissue Sample;Tissues;Tn5 transposase;tool;tool development;Translational Research;tumor;user-friendly;Validation;Visualization;web portal

PROJECT_TITLE: Scalable and quantitative chromatin profiling from formalin-fixed paraffin-embedded samples

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 MCST-G (15)]


NIH_SPENDING_CATS: Acquired Cognitive Impairment;Aging;Alzheimer's Disease;Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD);Biotechnology;Brain Disorders;Dementia;Genetics;Human Genome;Neurodegenerative;Neurosciences

PHR: PROJECT NARRATIVE Persistence of stable R-loops is strongly associated with genome instability, aging, and neurodegenerative disorders. Genome-wide profiling of R-loops may unlock new insights into aging and related disease mechanisms (and biomarkers for same), however existing approaches are insufficient for this work. Here, EpiCypher is developing a novel modular approach for genome-wide R-loop profiling that is sensitive, reliable, quantitative, and high-throughput to enable the next generation of aging and neurodegenerative disease research.

PI_NAMEs: VENTERS, BRYAN J (contact)

PROGRAM_OFFICER_NAME: BENNANI-BAITI, MICHAEL

PROJECT_TERMS: Acceleration;Affinity;Affinity Chromatography;age acceleration;Aging;Alzheimer's disease brain;Alzheimer's disease related dementia;Antibodies;Automobile Driving;Basic Science;Biological Assay;Biological Markers;Brain;brain tissue;Cell Culture Techniques;Cell Nucleus;Cell Physiology;Cells;Chromatin;Cleavage Under Targets and Release Using Nuclease;Clinical;clinical application;Clinical Research;commercialization;cross reactivity;Cultured Cells;Data;Detection;Development;Disease;DNA;DNA Damage;drug development;ds-DNA;Enzymes;Gene Expression Regulation;Generations;Genetic Transcription;genome-wide;Genomic approach;Genomic Instability;Genomics;Hybrids;in vivo;Incubated;innovation;insight;Invaded;manufacture;Maps;Marketing;Micrococcal Nuclease;Modeling;Monitor;Morphologic artifacts;Nature;Neurodegenerative Disorders;next generation;novel;novel marker;novel strategies;novel therapeutics;nucleic acid structure;Nucleosomes;Phase;Play;Production;promoter;Proteins;Protocols documentation;Quality Control;Reagent;Research;ribonuclease H1;RNA;Role;Sampling;Services;Single-Stranded DNA;Site;Structure;targeted nucleases;Technology;Tissues;Validation;Work

PROJECT_TITLE: Versatile platform for genome-wide R-loop mapping for aging and neurodegenerative disease research

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 NV-H (13)]


ORG_CITY: BIRMINGHAM

ORG_NAME: UNIVERSITY OF ALABAMA AT BIRMINGHAM

ORG_STATE: AL

PHR: Project Narrative Not Applicable

PI_NAMEs: DURANT, RAEGAN WINSTON;FOUAD, MONA N. (contact);TURNER, TIMOTHY

PROGRAM_OFFICER_NAME: CALZOLA, JESSICA MARIE

PROJECT_TERMS: African American;Alabama;American;Area;Award;Behavioral;Black race;Budgets;Cancer Cluster;candidate selection;Cardiovascular Diseases;Cardiovascular system;cohort;Collaborations;Community Medicine;cost;design;Diabetes Mellitus;diversity and inclusion;Doctor of Philosophy;Education;Elements;Ensure;expectation;experience;Facebook;Faculty;Family Practice;Female;Funding;Goals;health disparity;Infrastructure;Institution;Interview;Journals;Knowledge;Language;Latinx;Leadership;Letters;LinkedIn;Malignant Neoplasms;Medical;medical schools;Medicine;meetings;member;Minority;Minority Health Research;National Institute of Diabetes and Digestive and Kidney Diseases;Neurobiology;Neurosciences;Obesity;Operative Surgical Procedures;Positioning Attribute;Preventive Medicine;Process;Professional Organizations;programs;Psychiatry;Publications;Recommendation;recruit;Recruitment Activity;Research;Research Personnel;Resources;Schedule;Scientist;social media;symposium;timeline;Travel;United States National Institutes of Health;Universities;Update;virtual;Woman

PROJECT_TITLE: UAB/Tuskegee Faculty Institutional Recruitment for Sustainable Transformation (UAB/TU FIRST) Partnership (NIH U54) Travel Supplement


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Brain Disorders;Cancer;Cancer Genomics;Gene Therapy;Genetics;Human Genome;Huntington's Disease;Immunotherapy;Nanotechnology;Neurodegenerative;Neurosciences;Orphan Drug;Prostate Cancer;Rare Diseases;Urologic Diseases

ORG_CITY: CHICAGO

ORG_NAME: NUAGO THERAPEUTICS INC

PHR: PROJECT NARRATIVE New and more effective treatments are needed for advanced prostate cancer, especially for patients whose tumors have become resistant to anti-androgen therapy. NUAgo Therapeutics, Inc. is developing a new, RNA- interference-based therapeutic that kills cancer cells by leveraging a naturally occurring anti-cancer mechanism and is delivered by lipid nanoparticles. The mechanism of action leads to cancer cell death selectivity without the need for targeted delivery and is predicted to avoid the emergence of resistance, potentially allowing effective long-term treatment with fewer or less-severe side effects for patients living with prostate cancer.

PI_NAMEs: PETER, MARCUS E.;SCHICKEL, ROBERT  (contact)

PROGRAM_OFFICER_NAME: REGMI, SAROJ GOPAL

PROJECT_TERMS: 3' Untranslated Regions;advanced prostate cancer;Aftercare;aged;Alpha Particles;androgen independent prostate cancer;Androgen Receptor;Anti-androgen Therapy;anti-cancer;antitumor effect;AR gene;CAG repeat;cancer cell;Cancer cell line;Cancer Etiology;cancer therapy;Castration;Cell Death;Cell Proliferation;Cell Survival;Cells;Cessation of life;Clinical Trials;clinically relevant;comparison control;CUG repeat;Cytotoxic agent;Data;delivery vehicle;Development;Diagnosis;Disease;Distant Metastasis;effective therapy;efficacy testing;Enzymes;experimental study;FDA approved;first-in-human;Fluorescence;Formulation;Future;Gene Expression;Gene Expression Profiling;Genes;Genetically Engineered Mouse;Genomic Instability;Goals;Histologic;hormone therapy;Human;Huntington Disease;Huntington gene;Immunotherapy;immunotherapy trials;improved;in vivo;in vivo Model;Incidence;Intravenous;Kennedy Syndrome;Label;Lead;lipid nanoparticle;Liver;Magnetic Resonance Imaging;male;Malignant neoplasm of liver;Malignant neoplasm of ovary;Malignant neoplasm of prostate;Malignant Neoplasms;Measurement;Measures;men;Messenger RNA;Modeling;Monitor;mouse model;Mus;nanoparticle;neoplastic cell;Neurodegenerative Disorders;Neuroendocrine Prostate Cancer;new therapeutic target;Normal Cell;Normal tissue morphology;novel;novel therapeutic intervention;novel therapeutics;Oral;Outcome;Pathologic;patient population;Patients;Pharmaceutical Preparations;Phase;pre-clinical;Predisposition;Preparation;prevent;Production;prostate cancer cell;prostate cancer model;Prostate Cancer therapy;protein biomarkers;Receptor Signaling;Relapse;Reporter Genes;Research;Resistance;response;Risk;RNA;RNA Binding;RNA Interference;side effect;single-cell RNA sequencing;Small Business Technology Transfer Research;Small Interfering RNA;Specificity;Spinobulbar Muscular Atrophy;Stains;targeted delivery;targeted treatment;Testing;Therapeutic;therapeutically effective;therapy resistant;Tissue Sample;Tissues;Toxic effect;Transcript;transcriptome sequencing;transplant model;treatment effect;treatment optimization;treatment response;tumor;tumor growth;tumor heterogeneity;Tumor Tissue;Tumor Volume;ultrasound;United States;Universities;uptake;Variant;Venus;Western Blotting;Work;Xenograft Model;Xenograft procedure

PROJECT_TITLE: Development of a novel, RNA-interference-based therapeutic to treat prostate cancer

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 CTH-T (10)]


NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Bioengineering;Mental Health;Networking and Information Technology R&D (NITRD);Neurosciences

ORG_CITY: CHAMPAIGN

ORG_NAME: NEUROLUX, INC.

PHR: PROJECT NARRATIVE The proposed program integrates closed-loop optogenetic functionality (hardware and software) into a fully implantable, battery-free device for wireless data acquisition of physiological data including heart and respiratory rate, body temperature, and other behavioral information such as locomotion and orientation of rats and mice. This novel technology, which is fully compatible with the NeuroLux radio frequency wireless electronic platform, represents an important advanced tool for experimental behavior research that enables non-tethered, non- invasive operation in cages with simple or complex environments in individual or groups of animals.

PI_NAMEs: GOOD, CAMERON  (contact)

PROGRAM_OFFICER_NAME: DURKIN, JACLYN MARIE

PROJECT_TERMS: 3-Dimensional;Accelerometer;Acoustics;Adult;Anesthesia procedures;Animal Behavior;Animal Model;Animals;Arousal;awake;Behavior;behavior test;Behavioral;behavioral study;Bilateral;Bluetooth;Body Temperature;Brain;Chronic;Complex;Complication;Computer software;Computers;cost;Coupled;Custom;Data;data acquisition;data communication;Data Display;data exchange;design;Development;Devices;Drops;Electronics;Environment;Event;Feedback;file format;graphical user interface;Heart;Home;Implant;in vivo;in vivo evaluation;Individual;Industry Standard;Infrastructure;Intuition;Investigation;Laboratories;Location;Locomotion;lonely individuals;Magnetism;Marketing;Measurement;meetings;Methods;miniaturize;Monitor;monitoring device;Motion;Movement;Mus;Muscle;neural;Neurons;Neurosciences;new technology;novel;operation;Optics;optogenetics;Performance;performance tests;Peripheral;Phase;Physiological;Physiology;Power Sources;pre-clinical;Preclinical Drug Development;Procedures;Process;programs;pup;radio frequency;Rattus;Reader;Research;Research Personnel;Resolution;Respiration;respiratory;restraint;Rodent;sensor;Series;Signal Transduction;Small Business Innovation Research Grant;social;Social Behavior;Social Environment;social group;software systems;Sprague-Dawley Rats;Stream;System;Technology;technology platform;Temperature;Testing;Thinness;Time;time use;tool;Universities;usability;user friendly software;Validation;vibration;Washington;wireless;wireless electronic;wireless implant;wireless transmission;Work

PROJECT_TITLE: Wireless Implantable Mechano-Acoustic Recording Device

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 ISB-S (11)]


ADMINISTERING_IC: DA

IC_NAME: NATIONAL INSTITUTE ON DRUG ABUSE

NIH_SPENDING_CATS: Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Drug Abuse (NIDA only);Neurosciences;Opioid Misuse and Addiction;Opioids;Physical Injury - Accidents and Adverse Effects;Prevention;Substance Misuse

ORG_CITY: SAN ANTONIO

ORG_DEPT: PHARMACOLOGY

ORG_NAME: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER

PHR: PROJECT NARRATIVE That the opioid crisis continues despite the availability of medications that are effective in many patients, underscores the need for new, more effective therapeutics. This revised application requests support to continue developing the novel opioid receptor antagonist methocinnamox (MCAM) for preventing relapse after detoxification. GMP MCAM will be manufactured, an IND application will be submitted to the FDA, Phase 1 and Phase 1b clinical trials as well as additional non-clinical safety pharmacology and toxicology studies will be conducted. MCAM has the potential to fill the unmet need for an orally bioavailable, shelf-stable, long-acting medication for preventing relapse.

PI_NAMEs: FRANCE, CHARLES P (contact)

PROGRAM_OFFICER_NAME: RAMEY, TANYA S

PROJECT_TERMS: abuse liability;addiction;Address;Adult;Agonist;Agreement;analytical method;Anesthesia procedures;Biological Assay;Biological Availability;Buprenorphine;Canis familiaris;carfentanil;Clinical;clinical development;Clinical Management;Clinical Trials;Collaborations;commercialization;design;Development;developmental toxicity;Doctor of Philosophy;Dose;drug development;drug discovery;Drug Metabolic Detoxication;effectiveness testing;experience;Feedback;Fentanyl;Formulation;Funding;Future;Hour;improved;In Vitro;in vivo;Intellectual Property;Kilogram;Laboratories;Legal patent;Maleates;manufacture;Medicine;Methadone;Methocinnamox;micronucleus;mu opioid receptors;nalmefene;Naloxone;Naltrexone;National Institute of Drug Abuse;No-Observed-Adverse-Effect Level;nonhuman primate;novel;Opioid;Opioid Antagonist;opioid epidemic;opioid overdose;Opioid Receptor;opioid use;Oral;Overdose;Pain;Parents;Patients;Pharmaceutical Preparations;Pharmacodynamics;pharmacologic;Pharmacology and Toxicology;Pharmacology Study;Phase;Phase I Clinical Trials;Phase Ib Clinical Trial;Phase II Clinical Trials;Physiological;Plasma;pre-Investigational New Drug meeting;prevent;Prevention;Process;Program Development;programs;Property;Prophylactic treatment;Qualifying;Rattus;Recommendation;Relapse;relapse prevention;remifentanil;reproductive toxicity;Request for Applications;Research Contracts;Resources;response;Rodent;Route;Safety;scale up;Scientist;Secure;Sodium Chloride;Substance Use Disorder;Testing;therapeutically effective;Toxicology;U-Series Cooperative Agreements;United States National Institutes of Health;volunteer;weapons

PROJECT_TITLE: Development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing relapse and overdose

STUDY_SECTION: NIDA

STUDY_SECTION_NAME: Medication Development Research Study Section[NIDA-L]


NIH_SPENDING_CATS: Arthritis;Autoimmune Disease;Biotechnology;Cancer;Cervical Cancer;Clinical Research;Digestive Diseases;HIV/AIDS;HPV and/or Cervical Cancer Vaccines;Immunization;Immunotherapy;Infectious Diseases;Lupus;Patient Safety;Prevention;Rheumatoid Arthritis;Sexually Transmitted Infections;Transplantation;Vaccine Related;Women's Health Research

ORG_CITY: Oakland

ORG_NAME: KAISER FOUNDATION RESEARCH INSTITUTE

PHR: PROJECT NARRATIVE Immunocompromised people bear a much higher burden of human papillomavirus (HPV)-related anogenital disease compared with immunocompetent people; unfortunately, for immunocompromised people, studies evaluating the effectiveness of the HPV vaccine have been limited. In this study, we will evaluate HPV vaccine effectiveness to prevent anogenital condylomas, cervical and anal dysplasia/cancer in people with HIV, autoimmune conditions, and an organ or hematopoietic stem cell transplantation history. Findings will help optimize HPV vaccination strategies for immunocompromised people, including clarifying catch-up ages and potential boosting strategies.

PI_NAMEs: CHAO, CHUN R.;SILVERBERG, MICHAEL J (contact)

PROGRAM_OFFICER_NAME: CHUANG, ELEANORE JENNIFER

PROJECT_TERMS: Abdomen;Address;Age;Anal Intraepithelial Neoplasia;Antibodies;Antibody titer measurement;antiretroviral therapy;Anus;Archives;Attenuated;Autoimmune;Autoimmune Diseases;California;CD4 Lymphocyte Count;Cervical;Cervical dysplasia;Cervical Intraepithelial Neoplasia;Characteristics;Chest;Clinical;clinically relevant;cohort;Cohort Studies;comparison group;condyloma;Data;Disease;Dose;Dysplasia;Effectiveness;effectiveness evaluation;Electronic Health Record;Etiology;Evaluation;experience;Financial Hardship;General Population;Genotype;Guidelines;Heart;Hematopoietic Stem Cell Transplantation;high risk population;HIV;HPV-High Risk;Human Papilloma Virus Vaccination;Human Papilloma Virus Vaccine;Human Papilloma Virus-Related Malignant Neoplasm;Human Papillomavirus;Immune response;Immunocompetent;Immunocompromised Host;immunogenic;immunogenicity;immunosuppressed;Immunosuppression;Individual;Inflammatory Bowel Diseases;innovation;Integrated Health Care Systems;interest;Kidney;Knowledge;Lesion;Licensure;Liver;Longterm Follow-up;Lung;Malignant neoplasm of cervix uteri;Malignant Neoplasms;Medical;Morbidity - disease rate;mortality;Organ;Organ Transplantation;Outcome;Patients;Persons;Pharmaceutical Preparations;Population;Positioning Attribute;prevent;Prevention;Prevention strategy;randomized trial;Recommendation;Recording of previous events;Recurrence;Recurrent disease;Reporting;research clinical testing;Retrospective cohort study;Rheumatoid Arthritis;Risk;RNA;safety study;Sample Size;Sampling;seroconversion;Solid;Specimen;systemic autoimmune disease;Systemic Lupus Erythematosus;T cell response;Time;tissue archive;Translating;Transplant Recipients;Transplantation;Vaccination;vaccination outcome;vaccination strategy;vaccine effectiveness;vaccine evaluation;vaccine immunogenicity;vaccine safety;vaccine trial;vaccine-induced immunity;Vaccines;Woman

PROJECT_TITLE: Effectiveness of the HPV Vaccine in Immunocompromised Populations

STUDY_SECTION: HCAC

STUDY_SECTION_NAME: HIV Coinfections and HIV Associated Cancers Study Section[HCAC]


NIH_SPENDING_CATS: Bioengineering;Biotechnology;Cancer;Cooley's Anemia;Gene Therapy;Genetics;Hematology;Lymphatic Research;Lymphoma;Nanotechnology;Rare Diseases;Regenerative Medicine;Sickle Cell Disease;Stem Cell Research;Stem Cell Research - Nonembryonic - Human

ORG_CITY: SAN FRANCISCO

ORG_NAME: GIGAMUNE, INC.

PHR: PROJECT NARRATIVE Project Title: In vivo Sickle Cell Disease Gene Therapy Using a Novel Virus Like Particle Organization: GigaMune Inc. PI: David Johnson, Ph.D. Sickle cell disease is one of the most common genetic disorders and currently has no cure. There have been recent advances in cell therapies for sickle cell disease, but these methods remain expensive and can cause infertility. We are working on gene therapy methods that are cheaper and safer for patients.

PI_NAMEs: JOHNSON, DAVID SCOTT (contact)

PROGRAM_OFFICER_NAME: QASBA, PANKAJ

PROJECT_TERMS: Adenoviruses;Adult;Affect;American;Antibodies;autosome;B-Cell Lymphomas;Back;base editor;beta Globin;beta Thalassemia;Binding;Bioinformatics;Biotechnology;Bone Marrow Cells;Bone Marrow Purging;Busulfan;Capsid;Cardiomyopathies;CD34 gene;Cell Line;Cell Shape;Cell Therapy;cell type;Cells;cellular transduction;Circulation;Clustered Regularly Interspaced Short Palindromic Repeats;CRISPR therapeutics;Dependovirus;design;Disease;Doctor of Philosophy;Dose;Economics;Engineered Gene;Engineering;Enhancers;env Gene Products;Erythrocytes;Fetal Hemoglobin;Gene Cluster;gene therapy;gene-editing approach;Genes;Genetic Diseases;Genome;Globin;Goals;Grant;Hematopoietic stem cells;Hemoglobin;Hemoglobinopathies;high throughput screening;Hospitals;Human;human stem cells;in vitro Assay;in vivo;in vivo Model;Infertility;innovation;Iron Overload;Ischemia;Knock-in;Knock-out;Lentivirus;Life Expectancy;lipid nanoparticle;manufacture;Mediating;Membrane;Mendelian disorder;Methods;mouse model;mutant;Mutation;Nature;novel;novel virus;Occupations;organ injury;Paper;particle;Patients;Pharmacology;Phase;Pre-Clinical Model;Production;promoter;protein expression;Proteins;Proto-Oncogene Protein c-kit;Publishing;Research Personnel;Ribonucleoproteins;safe patient;Sales;seropositive;Shapes;Sickle Cell;Sickle Cell Anemia;sickling;Small Business Innovation Research Grant;Specificity;Stem Cell Factor;Structure;T-Lymphocyte;Technology;Testing;Training;transduction efficiency;transgene delivery;transgene expression;Transgenes;treatment center;Uncertainty;vaso-occlusive crisis;Virus-like particle;Work

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 IVBH-V (11)]


NIH_SPENDING_CATS: Bioengineering

ORG_CITY: CHAPEL HILL

ORG_DEPT: BIOLOGY

ORG_NAME: UNIV OF NORTH CAROLINA CHAPEL HILL

PHR: Project Narrative An animal cell, as a self-contained unit of life, contains all the components it needs to execute tasks like pinching in half. For example, cells possess a network of miniscule chemical motors and fibers that rearrange to generate the forces responsible for the cell shape changes. We use microscopes to gain magnified views of this dynamic network and to test how it rearranges differently if we manipulate one component at a time.

PI_NAMEs: MADDOX, AMY SHAUB (contact)

PROGRAM_OFFICER_NAME: MILLER, RITA K

PROJECT_TITLE: Mechanisms of cell shape change in cytokinesis

STUDY_SECTION: MRAC

STUDY_SECTION_NAME: Maximizing Investigators' Research Award C Study Section[MRAC]


NIH_SPENDING_CATS: Biotechnology;Cancer;Childhood Leukemia;Clinical Research;Gene Therapy;Genetics;Hematology;Immunotherapy;Orphan Drug;Pediatric;Pediatric Cancer;Prevention;Rare Diseases;Regenerative Medicine;Stem Cell Research;Stem Cell Research - Nonembryonic - Human;Transplantation

ORG_CITY: BUFFALO

ORG_NAME: ROSWELL PARK CANCER INSTITUTE CORP

PHR: PROJECT NARRATIVE While allogeneic hematopoietic cell transplantation can cure high risk leukemia, relapse and graft-versus-host disease (GVHD) account for over 60% of deaths post-transplant. Taking advantage of the differential expression of CD83 on acute myeloid and lymphoblastic leukemia, as well as effector cells of acute and chronic GVHD, we have developed human CD83-targeted chimeric antigen receptor (CAR) T cells that can simultaneously protect transplant recipients from relapse and GVHD. In this application, we will test human CD83-targeted CAR T in eliminating the two major causes of post-transplant mortality using established xenogeneic models and determine whether CD83 is a therapeutic target and biomarker of acute or chronic GVHD.

PI_NAMEs: BETTS, BRIAN C (contact);DAVILA, MARCO L.

PROGRAM_OFFICER_NAME: WELNIAK, LISBETH A

PROJECT_TERMS: Acute Graft Versus Host Disease;Acute Lymphocytic Leukemia;Acute Myelocytic Leukemia;Address;Aftercare;Allogenic;Antigens;antileukemic activity;antiviral immunity;B lymphoid malignancy;B-Cell Acute Lymphoblastic Leukemia;B-Lymphocytes;Binding;Biological Markers;biomarker validation;Blood specimen;CD19 Antigens;CD19 gene;CD4 Positive T Lymphocytes;CD8-Positive T-Lymphocytes;cell killing;Cell Line;Cell Therapy;Cell Transplantation;Cells;cellular transduction;Cessation of life;chimeric antigen receptor;chimeric antigen receptor T cells;chronic graft versus host disease;Clinical;clinical biomarkers;clinical translation;Clinical Trials;Colony-Forming Units Assay;Cyclophosphamide;cytotoxicity;Data;differential expression;Disease;disorder prevention;Effector Cell;experimental study;FDA approved;graft vs host disease;graft vs leukemia effect;Hematopoiesis;Hematopoietic Stem Cell Transplantation;Hematopoietic stem cells;high risk;Human;Immunoglobulins;Immunosuppression;Impairment;improved;improved outcome;in vivo;Infusion procedures;innovation;Kinetics;Knowledge;leukemia;leukemia relapse;Life;Link;Logic;Luciferases;Lymphoblastic Leukemia;member;Modeling;mortality;Mus;Myelogenous;Myeloid Leukemia;Myeloid Progenitor Cells;neutrophil;novel;Onset of illness;Outcome;overexpression;patient derived xenograft model;Patients;pharmacologic;phase I trial;post-transplant;post-transplant disease;potential biomarker;preservation;prevent;Prognosis;Prognostic Marker;Progression-Free Survivals;Prophylactic treatment;prospective;Recurrent disease;Regulatory T-Lymphocyte;Relapse;relapse prevention;relapse risk;Risk;Source;stem cells;success;T-Cell Activation;T-Lymphocyte;Tacrolimus;Testing;therapeutic biomarker;therapeutic target;tool;Toxic effect;transplant centers;Transplant Recipients;Transplantation;treatment response;tumor;validation studies;Viral;Work

PROJECT_TITLE: Targeting CD83 to reduce leukemia relapse and GVHD after allogeneichematopoietic cell transplantation

STUDY_SECTION: CII

STUDY_SECTION_NAME: Cancer Immunopathology and Immunotherapy Study Section[CII]


ED_INST_TYPE: GRADUATE SCHOOLS

NIH_SPENDING_CATS: Basic Behavioral and Social Science;Behavioral and Social Science;Cardiovascular;Clinical Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Nutrition;Obesity;Pediatric;Physical Activity;Prevention;Racial and Ethnic Minority Health Research;Social Determinants of Health

ORG_CITY: BRONX

ORG_DEPT: PSYCHOLOGY

ORG_NAME: FORDHAM UNIVERSITY

PHR: 8. PROJECT NARRATIVE Hispanic-Serving Institutions are institutions of higher education that prioritize supporting low-socioeconomic position students of color through their educational experiences; these institutions’ efforts may also promote health among diverse young adult populations. The design of this study allows us to longitudinally examine the economic and educational determinants of cardiometabolic health among diverse emerging adults, which are not yet comprehensively understood. Our study will help identify modifiable risk and protective factors from the economic and education sectors that could be targets for interventions to promote positive health behaviors and reduce risk of negative cardiometabolic health outcomes among emerging adults.

PI_NAMEs: COHEN, ALISON ;HOYT, LINDSAY TILL (contact)

PROGRAM_OFFICER_NAME: REIS, JARED P

PROJECT_TERMS: Academic support;Address;Adult;Affect;Affinity;Age;aged;Asian;Behavior;Behavioral;Binge Eating;Biological;Black race;Blood Pressure;Body mass index;California;cardiometabolic risk;cardiometabolism;Cardiovascular Diseases;cardiovascular health;career;Cellular Phone;Chronic Disease;Classification;college;Color;Complex;Country;COVID-19 pandemic;Data;Data Reporting;design;Development;diaries;Diet;Disease Outcome;disorder prevention;Eating Disorders;economic determinant;Economic Factors;Economics;Education;emerging adult;emerging adulthood;Employment;Enrollment;Environment;Ethnic Origin;experience;Financial Hardship;Food;Gender;Gender Identity;graduate school;Green space;Health;Health behavior;health determinants;health inequalities;Health Promotion;Heart Diseases;High Prevalence;high school;higher education;Hispanic;Hispanic-serving Institution;Household;Housing;Hypertension;Incidence;Income;Individual;Institution;Intervention;Joints;Latinx;Life Cycle Stages;Link;Longitudinal cohort;Longitudinal cohort study;low socioeconomic status;Marketing;Measures;Mediating;Mediation;Modeling;modifiable risk;novel;Obesity;Observational Study;older adult;Outcome;Overweight;Pathway interactions;Patient Self-Report;Perception;person centered;Persons;Phase;Physical activity;Physical environment;Population;population health;Population Heterogeneity;protective factors;Race;racial identity;recruit;Reduce health disparities;Reporting;Research;Risk;Risk Factors;Risk Reduction;Safety;Sampling;Security;sedentary lifestyle;Services;Shapes;Sleep;Smoking;social culture;Social Environment;social health determinants;Social status;Social support;Socioeconomic Status;socioeconomics;Stress;stressor;Student recruitment;Students;Surveys;Teenagers;Time;undergraduate student;United States;university student;Weight;Weights and Measures;young adult

PROJECT_TITLE: The 3E Study: Economic and Educational Contributions to Emerging Adult Cardiometabolic Health

STUDY_SECTION: SSPA

STUDY_SECTION_NAME: Social Sciences and Population Studies A Study Section[SSPA]


ADMINISTERING_IC: AA

IC_NAME: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

NIH_SPENDING_CATS: Alcoholism, Alcohol Use and Health;Chronic Liver Disease and Cirrhosis;Digestive Diseases;HIV/AIDS;Infectious Diseases;Liver Disease;Substance Misuse

ORG_CITY: OMAHA

ORG_NAME: UNIVERSITY OF NEBRASKA MEDICAL CENTER

ORG_STATE: NE

PHR: PROJECT NARRATIVE HIV-induced liver injury is the second-leading cause of mortality in HIV-infected patients. Rapid progression of liver fibrosis is frequently associated with alcohol, but the mechanisms are not clear yet. Here, we are examining how ethanol metabolism by suppressing HIV protein ISGylation in hepatocytes, sorts these non-ISGylated proteins to exosomes to induce the pro-fibrotic activation of hepatic stellate cells after engulfment of exosomes, thereby promoting liver fibrosis development.

PI_NAMEs: OSNA, NATALIA ALEKSANDR (contact)

PROGRAM_OFFICER_NAME: LIN, LI

PROJECT_TERMS: abuse victim;Acetaldehyde;Affect;Alcohol abuse;Alcohol consumption;alcohol effect;alcohol exposure;alcohol response;alcohol use disorder;Alcoholic beverage heavy drinker;Alcohols;antiretroviral therapy;Apoptotic;associated symptom;Automobile Driving;Cardiovascular system;Cause of Death;Cell Communication;Cell Death;Cells;Cessation of life;Chemosensitization;Chronic;Classification;clinical practice;Clinical Trials;co-infection;cohort;comorbidity;Data;Defect;Development;Disease Progression;Equus caballus;Ethanol;Ethanol Metabolism;Event;exosome;experimental study;Exposure to;extracellular vesicles;Fibrosis;Frequencies;Functional disorder;Future;General Population;Genes;Goals;Hepatic;Hepatic Stellate Cell;Hepatitis Viruses;Hepatocyte;Hepatotoxicity;HIV;HIV Core Protein p24;HIV-1;Impairment;improved;In Vitro;in vivo;Individual;Infection;Inflammation;Interferons;ISG15 gene;Kidney;Knockout Mice;Liver;Liver diseases;Liver Failure;Liver Fibrosis;liver injury;Lysosomes;Mediating;Modality;Modernization;Morbidity - disease rate;mortality;Natural Immunity;Nerve Degeneration;Organ;Outcome;Oxidative Stress Induction;Pathogenesis;Pathologic;Pathology;Patients;permissiveness;Persons;Play;Population;Post-Translational Protein Processing;pre-clinical;prevent;Prevention;Production;programs;Property;protein degradation;Protein Secretion;Protein Sortings;Proteins;Proviruses;Public Health;Regimen;RNA;Role;Sorting;Structure;Testing;Therapeutic Intervention;Toxic effect;translational potential;transmission process;Ubiquitin;Viral;Virus;Virus Diseases

PROJECT_TITLE: Non-ISGylated HIV proteins are sorted to hepatic exosomes to activate liver fibrosi

STUDY_SECTION: HCCS

STUDY_SECTION_NAME: HIV Comorbidities and Clinical Studies Study Section[HCCS]


ORG_CITY: RESEARCH TRIANGLE PARK

ORG_NAME: RESEARCH TRIANGLE INSTITUTE

PI_NAMEs: NOLEN, TRACY L;THOMAS, SONIA M (contact)

PROGRAM_OFFICER_NAME: PUNTURIERI, ANTONELLO

PROJECT_TERMS: Address;Adoption;Area;Behavior Therapy;Biological Products;Biometry;Blood;Blood Vessels;Cardiovascular system;Clinic;Clinical;clinical practice;Clinical Research;clinical research site;Clinical Trials;Clinical Trials Design;Clinical Trials Network;Collaborations;Communication;Complex;Consensus;COVID-19;COVID-19 intervention;COVID-19 pandemic;COVID-19 treatment;Critical Care;Data Collection;Data Coordinating Center;data harmonization;data quality;data standards;design;Development;Devices;Doctor of Philosophy;Documentation;Effectiveness;Ensure;experience;flexibility;Funding;Goals;Heart;Human Resources;Image;Industry;Informatics;informatics tool;Information Dissemination;Infrastructure;insight;International;Knowledge;knowledge base;knowledgebase;Lead;Leadership;Lung;Medical;Medicine;National Heart, Lung, and Blood Institute;North Carolina;Online Systems;operation;Operative Surgical Procedures;Outcome;Pharmaceutical Preparations;Phase;Principal Investigator;Process;professor;programs;protocol development;Qualifying;Ramp;Reporting;Research;Research Design;Resources;Role;Running;Scientist;Site;sound;Speed;Standardization;Statistical Data Interpretation;targeted treatment;Technology;Therapeutic;therapy development;Time;United States National Institutes of Health;Universities;Validation

PROJECT_TITLE: ACTIV Integration of Host-targeting Therapies for COVID-19 Administrative Coordinating Center

SUFFIX: SE


NIH_SPENDING_CATS: Behavioral and Social Science;Clinical Research;Clinical Trials and Supportive Activities;Dissemination and Implementation Research;Health Disparities Research;Health Disparities and Racial or Ethnic Minority Health Research;Mental Health;Pediatric;Prevention;Social Determinants of Health

ORG_CITY: GOLDEN

ORG_NAME: KLEIN BUENDEL, INC.

ORG_STATE: CO

PHR: PROJECT NARRATIVE Positive parenting practices help support optimal child social and emotional development. Parent training is considered a gold standard for supporting and strengthening parenting practices and for the treatment and prevention of child behavior problems. This study will develop and test a comprehensive implementation package (the ezParent Bundle) supporting the hybrid delivery of the ezParent Program with the goal of creating sustainable and accessible methods for community-based delivery.

PI_NAMEs: BREITENSTEIN, SUSAN M (contact)

PROGRAM_OFFICER_NAME: PARSAFAR, PARISA

PROJECT_TERMS: 5 year old;Address;Administrator;Adoption;Adverse event;Affect;aged;Aggressive behavior;arm;Behavioral;behavioral health;Buffers;Chicago;Child;Child Behavior;Child Care;Child Rearing;Childhood;Cluster randomized trial;Collaborations;Communities;community advisory board;community organizations;COVID-19 pandemic;Custom;dashboard;Dedications;design;Development;digital;Effectiveness;Emotional;Environment;evidence base;Exhibits;Feedback;foster parent;Goals;Head Start Program;Home;Human;Human Resources;Hybrids;implementation outcomes;improved;Individual;Intervention;Loudness;Low Income Population;lower income families;Maintenance;member;Methodology;Methods;Minority;Modeling;Monitor;National Institute of Child Health and Human Development;online delivery;Online Systems;Outcome;Parent-Child Relations;parental monitoring;parenting intervention;Parents;pediatric trauma;Persons;Phase;Preschool Child;prevent;Prevention;Problem behavior;program dissemination;Program Sustainability;programs;prototype;Reporting;Research;Schedule;Self Administration;Self Efficacy;Site;skills;Small Business Technology Transfer Research;social;social stigma;System;Technology;Testing;Time;tool;Training;Training Activity;Training Programs;Transportation;treatment as usual;underserved community;Underserved Population;uptake;usability;user centered design;web site

PROJECT_TITLE: Hybrid Delivery to Increase Access and Sustainability: Evaluating ezParent Implementation

STUDY_SECTION_NAME: Special Emphasis Panel[ZRG1 SCIL-D (10)]


ORG_CITY: PHILADELPHIA

ORG_NAME: ECOG-ACRIN MEDICAL RESEARCH FOUNDATION

ORG_STATE: PA

PHR: Please see the original BIQSFP application for each study.

PI_NAMEs: ODWYER, PETER J (contact);SCHNALL, MITCHELL D.

PROGRAM_OFFICER_NAME: MOONEY, MARGARET M

PROJECT_TERMS: American College of Radiology Imaging Network;Eastern Cooperative Oncology Group;operation

PROJECT_TITLE: ECOG-ACRIN Network Group Operations Center - BIQSFP


ADMINISTERING_IC: NS

IC_NAME: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NIH_SPENDING_CATS: Brain Disorders;Clinical Research;Clinical Trials and Supportive Activities;Comparative Effectiveness Research;Complementary and Integrative Health;Emergency Care;Hyperbaric Oxygen;Lung;Neurosciences;Physical Injury - Accidents and Adverse Effects;Traumatic Brain Injury (TBI);Traumatic Head and Spine Injury

ORG_CITY: MINNEAPOLIS

ORG_NAME: HENNEPIN HEALTHCARE RESEARCH INSTITUTE

PHR: RELEVANCE  The human and economic consequences of severe TBI are enormous. Despite approximately 30 clinical trials evaluating various treatments for severe TBI, a specific treatment has been elusive. Hyperbaric oxygen provides one of the best opportunities for demonstrating a specific treatment for severe TBI. If successful, the human and economic benefits to society worldwide would be great.

PI_NAMEs: BARSAN, WILLIAM G;GAJEWSKI, BYRON J.;KORLEY, FREDERICK KOFI;ROCKSWOLD, GAYLAN L (contact)

PROGRAM_OFFICER_NAME: SCOTT, GRETCHEN CARLYLE

PROJECT_TERMS: Brain;brain cell;Brain Injuries;Cell Death;Clinical;clinical investigation;Clinical Trials;Conduct Clinical Trials;Data;design;Dose;Economics;efficacy study;efficacy trial;Ensure;Failure;Frequencies;Funding;Human;Hyperbaric Oxygen;Hyperbaric Oxygenation;improved;improved outcome;Investigation;Lung;lung injury;mortality;National Institute of Neurological Disorders and Stroke;Neurological emergencies;Outcome;Oxygen;oxygen toxicity;Patients;Phase;phase III trial;pre-clinical;Predisposition;pressure;Probability;Production;Schedule;Societies;standard care;TBI Patients;Traumatic Brain Injury;Treatment Protocols;treatment trial;ventilator-associated pneumonia

PROJECT_TITLE: Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial - CCC


NIH_SPENDING_CATS: Autoimmune Disease;Clinical Research;Genetics;Health Disparities and Racial or Ethnic Minority Health Research;Lupus;Racial and Ethnic Minority Health Research

PHR: Project Narrative: Systemic lupus erythematosus is a devasting disease that affects over one million Americans of African, Hispanic, Asian, and Native American Ancestry. We propose to study how defective repair of DNA in combination with environmental exposures leads to the development of lupus.

PI_NAMEs: SWEASY, JOANN B. (contact)

PROGRAM_OFFICER_NAME: HEACOCK, MICHELLE

PROJECT_TERMS: Address;Affect;African American;African American population;African ancestry;Agreement;American;Antinuclear Antibodies;Asian Americans;Asian population;Autoantibodies;Autoimmune Diseases;base;Biochemical;chronic autoimmune disease;Code;Collaborations;Development;Disease;disease model;DNA Repair;DNA Repair Gene;Environment;Environmental Exposure;European ancestry;gene environment interaction;Genetic;Genetic Code;Genetic Predisposition to Disease;genetic variant;Germ-Line Mutation;Hispanic;Hispanic Americans;Immunoglobulin Somatic Hypermutation;Individual;insight;Laboratories;Link;Lung Diseases;Lupus;men;Mismatch Repair;Molecular;Monozygotic twins;mouse model;Mus;Mutation;Native American Ancestry;Native Americans;Organism;Pathology;Pathway interactions;Persons;Play;POLB gene;Production;Research;response;Role;Systemic Lupus Erythematosus;V(D)J Recombination;Variant;Woman;Work

PROJECT_TITLE: Aberrant DNA Repair and Lupus


NIH_SPENDING_CATS: Clinical Research;Clinical Trials and Supportive Activities

ORG_CITY: SEATTLE

ORG_NAME: BENAROYA RESEARCH INST AT VIRGINIA MASON

ORG_STATE: WA

PHR: Project Narrative The proposed ITN UM1 funding addresses major unmet health needs. In the United States, autoimmune diseases affect >5% of the population, and allergic diseases affect another ~15%. Transplantation is a life- saving intervention for organ failure, but risky and burdensome. In each area, pre-clinical studies show that immune tolerance should be an achievable therapeutic prospect, and progress towards that goal is evident in recent clinical trials. Successful tolerance offers long-term freedom from immunosuppressive therapy, radically improving quality of life, disease burden, and health care costs.

PI_NAMEs: ANDERSON, MARK S;BUCKNER, JANE HOYT (contact)

PROGRAM_OFFICER_NAME: THOMAS, LEIGHTON A

PROJECT_TERMS: Acceleration;Address;Adopted;Affect;Allergic Disease;Area;Autoimmune Diseases;Autoimmunity;burden of illness;California;Clinical;clinical application;Clinical assessments;Clinical Research;clinical research site;Clinical Trials;Communities;Complex;Creativeness;data sharing;design;Development;Discipline;Disease;Ensure;flexibility;Fostering;Freedom;Funding;Future;Genetic;Goals;Grant;Health;Health Care Costs;Homeostasis;Hypersensitivity;Immune;Immune Tolerance;Immunologics;Immunology;Immunosuppression;improved;Industry;innovation;Institution;Intervention;Knowledge;Laboratories;Lead;Leadership;Life;Medical;Mission;next generation;novel;operation;Organ failure;Peer Review;Pharmacotherapy;Population;preclinical study;Process;programs;Protocols documentation;Publications;Quality of life;Research;Research Institute;Research Personnel;Resource Sharing;Risk;Role;San Francisco;Structure;success;Testing;Therapeutic;Therapeutic immunosuppression;Tissues;Transplantation;treatment response;trial design;trial planning;United States;Universities

PROJECT_TITLE: Immune Tolerance Network UM1 2023 Supplement